Podcasts about Wistar Institute

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yard work. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with James Lovett, CEO and Mike Cohen, Executive Chairman at Myonex. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with James and Mike, covering: How a family-owned pharmacy became a major global clinical trial supplies business... two generations later Mike's decision to bring in a CEO and the challenge of letting go... before seeing the data points of success James' decision to take on the baton and fuel organic and inorganic growth through client-centricity The decision not to take investment and instead 'run our own play' using some of PE's tried and tested playbook Why this industry will always grow due to unmet medical needs and breakthroughs in science Michael's passion and commitment have been a driving force in making Myonex, a global leader in clinical trial supply. Under his leadership, Myonex has expanded its service offerings and strengthened manufacturer and sourcing relationships, opened new locations and expanded the employee base. Today Michael focuses on strategic growth opportunities. Before Myonex, he served in executive positions in the publishing, advertising, financial and utility industries. He holds a BS in Statistics from the University of Pittsburgh and an MBA from the university's Katz Graduate School of Business. James is driven to help clients deliver medical advances, to develop team members, and to lead Myonex to continued success. Before joining Myonex in 2017 as Chief Operating Officer, James was SVP of Covance, where he led three business units, was General Counsel and served on the Executive Committee. He was named Myonex CEO in 2019. He also serves on the Board of Directors of Food Chain ID and the Board of Trustees of the Wistar Institute. James has played leadership roles in the Association of Clinical Research Organizations and the National Association for Biomedical Research. He is a graduate of Northwestern University and Harvard Law School.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of The Wistar Institute's podcast, Dr. Maureen Murphy touches upon the science of life—in the lab and beyond. She focuses on her cancer research career connected to social consciousness, but also writing well, poetry, politics, and nature.

Learn about the history, purpose and work of the Hispanic National Bar Association's Health & Life Sciences section, as shared by its co-chairs, Gelvina Rodriguez Stevenson, general counsel at the Wistar Institute and Mildred Segura, litigation partner at Reed Smith. The discussion will be moderated by Anna Lozoya from Sentara Health. ----more---- Transcript: Intro: Welcome to the Reed Smith podcast, Inclusivity Included, Powerful Personal Stories. In each episode of this podcast, our guests will share their personal stories, passions and challenges, past and present, all with the goal of bringing people together and learning more about others. You might be surprised by what we all have in common, inclusivity included.  Anna: Welcome back to Inclusivity Included. And today's episode is in partnership with the Hispanic National Bar Association. And today we'll be learning about the Health and Life Sciences section, along with co-chairs Gelvina Rodriguez-Stevenson and Mildred Segura. Gelvina Rodriguez is the General Counsel and Corporate Secretary at Wistar Institution, an international biomedical institute. Gelvina's career spans various sectors of the healthcare industry, including hospitals, academic medical centers, and pharmaceutical companies in government. Gelvina serves as the co-chair of the Hispanic National Bar Association's Health and Life Sciences Section and as a board member of the American Health Law Association. Mildred Segura is a litigation partner at Reed Smith LLP, a full-service global law firm. She is based in Los Angeles and is a member of Reed Smith's Life Sciences Health and Industry Group, specializing in complex products liability litigation, matters focused on medical device and pharmaceutical litigation in state and federal courts across the United States. Well, Mildred and Gelvina, excited to have you here so we can learn more about the Health and Life Sciences section of HNBA. Gelvina, can you give the audience a brief history of what was the inspiration to create the section and a brief overview of the history of the section?  Gelvina: Yeah, great, Anna. Thank you. Thank you for that that introduction for putting together this session. Very happy to talk about the health and life sciences section of the HNBA. So we started this section of the HNBA years ago. And, you know, really the idea came when I had started my first in-house job, and it just happened to be in the health sector. It was at an academic medical college. And, you know, I got there. I was like, oh, I don't know anything about health law. So let me, you know, look for mentors. And I've been fortunate through my career to always be able to find, you know, wonderful mentors through the HNBA and, you know, LaLSA, when in law school. And I started looking around to find other attorneys who were in this sector and really couldn't find anyone. I looked around, you know, my, the legal department where I was, you know, other organizations and just really couldn't find any mentors, role models to figure out how to navigate this area. So, you know, having always been active with the HNBA, you know, doing law school and having served as a regional president for the HNBA, I knew that there were very active sections within the HNBA in other areas, business law, labor and employment, employment, compliance. And I thought, gosh, it'd be great if there were a health law section where I could meet other Latino and Latina lawyers working in this space and kind of learn how it works. So I proposed to leadership at the HNBA the idea of forming this section. They thought it was a great idea, and it was formed. So then at that point, sections formed, and we had to build the community. So basically, me and our co-chair reached out to people we knew who were in you know, pharmaceutical device companies, hospitals, and invited them to join. And then also when you're part of the HNBA, you can check off what section you're interested in joining. So we had members join that way. And, you know, over the years, it's grown to be a really wonderful network of Latino and Latino lawyers across the country who are either working in healthcare and life sciences or interested in it. And it really has become, you know, that mentoring, you know group that what didn't exist years ago so really really excited to you know have that come to fruition have it become what it's become.  Anna: That sounds like really great work and it sounds like we needed that and you recognized that was something we needed so good work there and and for contributing that.  Gelvina: yeah and so wonderful that the HNBA was just so open and willing to you know jump on a new idea and move it forward so that's always wonderful.  Anna: Yeah yeah definitely HNBA is It's big about innovating. And as we grow as a legal community as well, expanding to meet the needs of the members. But I'm sure Mildred, as it sounds from Gelvina, that this is growing and growing. What do you find to be the most rewarding and most challenging aspects of co-chairing this vastly growing and expanding section here?  Mildred: That's a great question, Anna. And I've been co-chair, Gelvina invited me to serve in that position maybe three, four years ago now, Gelvina, maybe, right? And prior to that, there were other co-chairs. But I know Gelvina has been there since inception, as she just described. And I would say, you know, during my tenure these last couple of years, I would say the most rewarding aspect of co-chairing the section has been the opportunity to make a tangible impact on our community, which is health and life sciences, lawyers, policymakers, students, right? People who are interested in maybe getting into this space or maybe don't even have a clue what the space really is. And I've had the privilege of working with really, you know, brilliant people like Gelvina, like yourself, Anna, and others that are in our section and learning just how vast this practice area really is, right, of health and life sciences and how much it encompasses. Purposes and um and it's nice as Gelvina said you know it's a place of like-minded people doing you know they're in different practices but under the same umbrella and we're all our goal is the same right to advance health care and life sciences while ensuring that our voices are heard in these critical areas whether it's representing our clients you know in big law or in public interest or in the government and so wherever you are it's it's a nice sort of place to come together and be be able to showcase, you know, what's going on in your practice or in this area. And it's a really collaborative spirit as well, where people bring ideas. You know, if someone comes to us and say, hey, I have an idea for a webinar that I want to put on, focused on health and life sciences, it's great, right? And we're learning as we go, too, because I'm a litigator. And so there may be ideas and trends that I'm not even aware of. So it's a really great way to stay abreast of what's going on in this space as well. And Gelvina mentioned mentoring. And so we do have students that are members. version. I would say that's the other rewarding aspect of this is the ability to mentor young attorneys is incredibly fulfilling, right? And we put on a CLE panel presentation at one of our corporate council conferences for the HNBA, which was focused on careers in life sciences and healthcare, because a lot of students have no clue, you know, well, what does that mean? You know, what kind of careers do you have within that space? And there was a panel of litigators, government attorneys, policymakers. Gelvina moderated that panel. I was on it as well. And it was great to see the type of questions that we were getting from these up-and-coming, soon-to-be lawyers. And on the flip side, you asked me what's been the most challenging. I would say is balancing the diverse interests of our members within the section, right? Because like I said, that I'm a litigator, Gelvina's in-house, we have people in government, you know, all across the board in transactional spaces. And so it's really, you know, trying to cater to our members, ensuring that we are responsive to their needs and what they're interested in. And so we try and cover a broad range of topics to ensure that we provide value to our members, which requires, you know, careful planning, constant communication. But these challenges also present opportunities for growth and innovation. Like I said, as a litigator, I'm learning a lot about other aspects of health and life sciences beyond what my firm offers, obviously, which also does a little bit of everything within the life sciences space. So that's what I would say have been the most rewarding and challenging aspects of being co-chair of the section.  Anna: Oh, that's a lot. But it sounds like you and Gelvina have a good handle of that and having such a wide spectrum of individuals from law students to seasoned attorneys. And it sounds like your panel regarding careers in health and life sciences really try to hold in on the great plethora of opportunities for someone who's interested in our great section, our section that we love.  Mildred: That's exactly right.  Anna: From this section's name, health and life sciences, Gelvina, who do you think should join this section? And like, what are the benefits of joining HNBA's Health and Life Sciences section?  Gelvina: Yep. So in terms of who should join, I think, you know, Mildred touched on this a bit. And I think she went over sort of the diversity of this field, right, and the breadth of who is a healthcare lawyer, who is a life sciences lawyer. And it's really anyone who's like, you know, knee deep in that space. Like you're on a hospital attorney or someone at a pharmaceutical company in healthcare and life sciences, or it could be someone just sort of interested in maybe exploring that space. Or it could be someone who's a litigator and they happen to have a case that involves two healthcare-related companies. They want to, you know, learn more about this space and how it works or just, you know, interact with people working in this space. It could be, you know, anyone from like the knee-deep healthcare life sciences lawyers to people who are just tangentially involved. And, you know, again, the spectrum there is hospital attorneys, pharmaceutical device company attorneys and other legal professionals, folks working in health tech, AI, which is huge in health care, health insurance companies. PBMs, pharmacies, labs, you know, government, AG offices do lots of the, you know, credentialing and licensing for health care providers. It's, you know, we cover topics in reproductive health, public health. We have lots of members who are working in the antitrust space. There's lots of activity and healthcare entities related to antitrust. So, you know, as you can see, public policy, Mildred mentioned that. And really just in terms of, you know, you asked about the benefits of joining. So, again, for the folks who are knee deep, like we get to, you know, get on these calls and say, you know, this is this topic that we're starting to see, you know, more of in our space. What are you all seeing? And just kind of share ideas and approaches. And, you know, for those who are not knee deep learning about the area, you know, and for students, you know, Mildred mentioned we have lots of students who join. And I think historically, healthcare and life sciences hasn't been like one of those key areas that you focus on in law school. It's not like, you know, securities, which is kind of all over. And so it's a new area. So we can provide, you know, mentoring and exposure to different career opportunities in this space, which is very exciting and growing. And we also coordinate with other organizations like the American Health Law Association and build liaisons there and share speaking opportunities that we're aware of that folks may want to be interested in, job opportunities. So I could go on and on forever about all the benefits of joining this section, but I'll pause there.  Anna: Thank you. I can definitely say I have benefited both from being a section member, from Gelvina's mentorship, which is a benefit. Mildred mentioned that it's having had the opportunity to present at the American Health Lawyers Association and also learning. I know we last year had someone present on privacy and AI and how that affects our our industry. And that was really great and insightful. I was like driving, but trying to take notes. And I'm like, I need to pay attention. And so it was just really enthralled and learned a lot. And I was able to take that back into my actual practice and still have. And it's been very impactful. So definitely a great benefit. And so really, really appreciative of the section doing that. And I have a question for both of you. Can each of you share how the section has influenced your practice and your personal life?  Gelvina: Yeah. You know, I think, like you said, just being able to meet other attorneys in this space like you and Mildred and, you know, work together. Yeah. And just finding that sense of community and others who've, you know, maybe are like in a field that I've been interested in or, and it's really just invigorating, right? Once you start looking for other Latino and Latina lawyers working in this space, we find each other and it's very inspiring. So, for example, we did a podcast series through the section where we interviewed Latino and Latina leaders in health care and life sciences. We, you know, for example, Lisa Pino, who was the director of the Office for Civil Rights within HHS, which is the office that enforces HIPAA, a really important position. So just being able to, you know, connect with her and, you know, expose our membership to people like her and really exciting positions like that. And, you know, she provided mentorship and advice on that call. Like, how do you get to these positions if you're interested? How do you navigate these positions as a Latina? So, you know, just being able to meet people and interact with people in this space has just been inspiring and made me feel very optimistic and supported in my career. So that's really been, you know, that's from a professional and personal, again, from a personal perspective, meeting other professionals who are working in similar space. You have so much in common and you can share so much. You become, you know, colleagues and friends, which is just wonderful. Yeah.  Mildred: Yeah, and I would echo a lot of what Gelvina just said in terms of just on a, in my practice alone, right, having immersed myself into the section, taken on the role of co-chair, having to learn sort of, okay, who's our membership? What are they interested in? But more than that really was the friendships that I've been able to build. Obviously, your network expands, right, which is always great. And just deepening my own understanding of health and life sciences. Like I said, I come from the litigation side of life sciences. So to be able to speak with you, Anna, about risk management issues that impact hospitals, for instance, right? And sort of those folks that are in that space is important because it helps inform perhaps how I may be counseling my clients on my end when it comes to the litigation side. So there's this cross-pollination. I think that's very beneficial and is one of the things that has greatly influenced my practice by virtue of serving as co-chair. And on a personal level, I would say that it's just reinforced my commitment to advocating for our community. It's nice, yes, we have a place of like-minded folks who can come together, share ideas, trends, and practices that cut across the health and life sciences space, but also what we do for the larger community. And one thing that HNBA offers is something called Advocacy Day, which is a day where HNBA members, section members can go to Congress, and we have various meetings with congressional representatives on issues of importance to our section. So as a health and life sciences section, we, you know, one issue that came to mind was on mental health, which is a key issue for the Latino community and something that can be, you know, has a lot of, could be taboo and a lot of, you know, people don't want to come forward and say, you know, I'm suffering from mental health and get the care that they need. So to me, that was the first time I participated in that advocacy date program. So to be able and have these meetings with, you know, the congressmen and congresswomen and be able to talk about these issues was really a different experience for me that I had not engaged in before. So I would say, you know, that experiences like that is something that our section offers and that I would recommend to anyone.  Gelvina: Yeah. And just to pick up on that point that Mildred just made, we also work very closely with the leadership of the health and life sciences section of the Asian American Bar Association, the South Asian NAPABA, SABA, and the NBA. And especially during the pandemic, we really were coordinating on health equity issues. And we did some publications for the HNBA on health equity to elevate being in a position where we could elevate those important topics. And as lawyers, a resource on how those issues impact our community from a legal perspective has been key. And, you know, to Mildred's point, being able to bring these important topics up at Advocacy Day has been a really important role for this committee.  Anna: Yeah, I think this section is really good at doing that, bringing forward not only our issues and what we need as section members, but also for the community at large. And not just professionally, but also just, you know, the overall Latino, Latina, Hispanic community across the U.S. I know we also have written, Gelvina and I and a few of us others, we wrote an article on how we could give back and give our skill sets since we have such a variety of skills across different spectrums of areas, whether it's helping with wills or sitting on a board. I know Gelvina sits on several boards and giving back in different ways to impact to ensure health care equity within our community and not just out in the sense of professional legal realm. Mildred, can you share any exciting initiatives that the section currently has and any that they might have going on in the future with our listeners?  Mildred: Sure. Good question. So, you know, right now our section is focused on a few key initiatives. One of them is creating more educational resources and webinars that address emerging issues in health and life sciences, particularly those affecting the Hispanic community, obviously, but also other trends that we're seeing that are of interest to our members. And we're also strengthening our mentorship program, aiming to provide guidance and support to the next generation of legal professionals in the field. This year, which kicked off in the fall of 2023, we kicked it off with a social media campaign, right? Because we know the younger generation is on Instagram and what used to be Twitter, so now X. And so HNBA has been really active in engaging with the social media platforms and getting the word out about sections like ours that are offered through the HMBA. So we had a social media campaign that featured myself, Gelvina, and you were part of that as well as our other vice chairs of the section to really get the word out about who we are, what's our mission, what's our purpose, right? We're here to serve you and to get more membership to join the section. So that's been one initiative in terms of just getting the word out. Other initiatives that we've taken on this year have been highlighting select members of our section on topics of interest. And we touched on this already earlier today. You know, we've had people from who are at the top pharma companies present on data privacy issues. We've had people within the medical device industry come and speak to us about what they're seeing relative to AI and life sciences and some of the implications coming out of that, both on the regulatory side and the litigation side, for instance. Instance, we had presentations on the impact of the recent FTC ruling on non-compete agreements, which now we have a federal court, right, who's come out and said, okay, you know, you don't have the authority to do that. So a lot of activity that's relevant to our section across the board, right, no matter whether you're in-house or at a firm or perhaps in government. And another initiative we had was focused on the Supreme Court's decision related to DOBS and reproductive health. And we put on a CLE panel at one of our corporate council conferences for the HNBA focused on sort of sexual and reproductive health post-DOBS, which was well attended and extremely timely just because of all the issues, you know, no matter what side you are on that issue, you know, it's always helpful to bring that to our community and have people, you know, have a discussion and a debate around those issues. More recently, coming up for our annual convention in September, taking place in D.C., we will have a panel focused on GLP-1 pharmaceuticals. It's called GLP-What? Exploring the Weighty Legal Issues of Pharma's Blockbuster Weight Loss Drug, which will feature our very own Anna, who's with us today, along with some other members of our section and the IP section of the HNBA. So we're looking forward to that. And we're busy working on some additional webinars coming up later this year, including one, like I said, on non-compete agreements, as well as because we are in election season, sort of the impact of the elections on health and life sciences. We know there's a lot of impact there and we want to be able to bring that to our members as well. And just getting creative, thinking outside the box. You know, this idea of this podcast, Anna, was yours. I thought, you know, it's a great idea. So initiatives like that, trying to get a little bit more creative in how we can, again, bring our section and the most value to our members as much as we can. And lastly, as Gelvina touched on, we're collaborating with other bar and healthcare-related organizations, such as the American Health Law Association, which you both touched on. And, yeah, so we're trying to do, you know, as much as we can, again, because, you know, we don't get paid for this. We do it because we like it, we want to. And it's, as Gelvina said, very inspiring and invigorating to be doing this work. So really lucky to have the opportunity to do it.  Anna: That's a lot of great work, a lot of great initiatives, and I look forward to that. I hope our listeners join us so you can learn. Even if you don't practice in this area, a lot of that expands and cross-pollinates and touches different aspects of our daily life. Gelvina, so where can people that are interested in learning more about this section and wanting to just find out when is the next podcast or when is the next webinar, where can they find us?  Gelvina: Yep, there's a number of ways. Number one, you can go on HNBA, Hispanic National Bar Association.com. And there's a drop down link to sections and you'll find the health section, health and life sciences section there. You can join that way. Also, as a member, you can join through your membership portal, but also you can join through the section portal. We have a LinkedIn page. It's HNBA Health and Life Sciences. So you can find us on LinkedIn and join that way. And we send out information about our upcoming events and activities via the LinkedIn page. On the LinkedIn page, there's also email addresses where you could email Mildred or me and we'll get you on the listserv. So we send out emails and calendar invites for the meetings. We usually have, as Mildred mentioned, a meeting at the annual conferences for the HNBA. There's two annual conferences a year, one in September and one in March. So we usually have an in-person meeting there. And then we have one to two virtual meetings throughout the year where folks can join. And like Mildred said, we have people present on topics of interest. But also, we start each of those meetings with everyone introducing themselves and where they work or what their interest is. And that's a really great way to get to know the community. So I would encourage folks to get on the LinkedIn page, join via the HNBA.com website, email us if you have any questions and, you know, come attend one of our meetings or activities.  Anna: Great. Thank you for sharing that. I want to thank everyone for joining us today here on Inclusivity Included in our partnership today with the Hispanic National Bar Association Health and Life Sciences section. Thank you, Gelvina and Mildred, taking time out of your busy days as co-chairs and sharing with us your experiences, your contributions, and as well as all the exciting new initiatives and planning that the section has. Please join us next time on our next episode on Inclusivity Included.  Outro: Inclusivity Included is a Reed Smith production. Our producers are Ali McCardell and Shannon Ryan. You can find our podcasts on Spotify, Apple Podcasts, Google Podcasts, reedsmith.com, and our social media accounts.  Disclaimer: This podcast is provided for educational purposes. It does not constitute legal advice and is not intended to establish an attorney-client relationship, nor is it intended to suggest or establish standards of care applicable to of particular lawyers in any given situation. Prior results do not guarantee a similar outcome. Any views, opinions, or comments made by any external guest speaker are not to be attributed to Reed Smith LLP or its individual lawyers.  All rights reserved.  Transcript is auto-generated.

In this episode, Dr. Stephanie and Dr. Joe debunk common cancer myths while highlighting the importance of a nutrient-rich diet. Learn about the relationship between fibre consumption and cancer, the benefits and misconceptions surrounding coffee, and the impact of gut health on cancer. Whether you're interested in the evolutionary aspects of cell biology or practical dietary strategies to support cancer treatment, this episode offers actionable insights for maintaining a healthy lifestyle and reducing cancer risks.Episode overview:0:00 Intro/Teaser03:40 Exploring the Nuances of Cancer13:36 Understanding Cancer19:14 Genetic Mutations and Cancer Risks33:00 Alcohol Metabolism and Cancer Risks41:54 Cancer Cell Metabolism and Dietary Interventions49:12 Dietary Interventions in Cancer Treatment1:00:32 Exercise and Immune System Function1:04:14 Nutrient-Rich Diet and Cancer Prevention1:11:45 Coffee Consumption and Cancer Risk1:15:40 Debunking Common Cancer MythsResources mentioned in this episode: https://drstephanieestima.com/podcasts/cancer-myths-realities-preventative-measures/Bio:Dr. Joe Zundell received his PhD in Cancer Biology from the Wistar Institute and The University of the Sciences in Philadelphia, PA. USA. Through over 10 years performing lab work, Joe specializes in understanding the metabolic, epigenetic, and genetic contributions for cancers. Currently, he works within the private sector at a biotech company looking to advance targeted radiopharmaceuticals to better treat solid cancers. In his free time, he educates the public on social media about the complexities of cancer biology and how people can reduce their risks for developing cancers.We are grateful to our sponsors:EQUIP collagenYou can use this grass-fed collagen daily, to take care of your hair, skin, nails, joints, and gut after resistance training workouts, or you can even bake with it because it tastes like dessert, not beef. Go to https://equipfoods.com/better and use the code BETTER for 20% off.TIMELINEFeeling tired and having no energy does not have to be your fate. Mitopure is a supplement and skin health line that helps improve energy at the level of the mitochondria so that you can continue to engage in the activities you love. Go to https://timelinenutrition.com/better and use code BETTER to get 10% off your orderAPOLLOThe Apollo wearable supports women's cycle and changing bodies by supporting the circadian and infradian rhythms so you can give your body what it needs when you need it — more energy, relaxation, focus, sleep, or calm. Go to https://apolloneuro.com/DRSTEPHANIE and use code DRSTEPHANIE for 15% off your order.

In this episode of The Wistar Institute's podcast, science educator Dr. Jason Diaz shares his passion for teaching, and how he brings Wistar Science into the classroom for diverse students from all backgrounds. Join us as we explore his drive to impart the hands-on skills and mindset needed to build the next-generation scientist.

We're bringing back an episode originally published in March 2023. Dr. Joe Zundell is a dedicated cancer biologist whose personal journey has driven his professional mission. Dr. Zundell opens up about losing his mother to esophageal cancer and how this pivotal experience led him to pursue a career in cancer research. With a bachelor's degree from St. Leo University and advanced studies in Philadelphia, Dr. Zundell's work has been published in prestigious journals, reflecting his deep commitment to understanding and combating cancer.Dr. Zundell shares invaluable insights into the complexities of cancer biology, the importance of personalized treatment approaches, and the profound impact of cancer therapies on patients' lives. He emphasizes the necessity of treating cancer patients with empathy and respect, challenging the notion that they are fragile and highlighting the importance of personalized physical therapy tailored to their unique needs. If you listen to this episode let us know! We'd love to hear from you. Tag us at @bsimpsonfitness on social! Help Us Help More People. When you leave a review on Apple or Spotify, it helps us share the message so that we can raise the industry standards and help more people for free. About the Guest Dr. Joe Zundell received his PhD in cancer biology through the University of the Sciences and The Wistar Institute in Philadelphia, PA. As a cancer biologist he has over 10 years of cancer research experience. Much of his published research has focused on finding new therapies for the treatment of many different cancer types upon epigenetic and metabolic characteristics of cancers. Currently, he is a Research Scientist at a biotherapeutic company near Philadelphia where he is examining Immunotherapies for treating cancers. Joe aims to develop and characterize therapies to enhance cancer patient outcomes. Secondly, he aims to produce educational tools to enable better scientific understanding and instructing. Thirdly, and lastly, he aims to have his own lab with his own projects to progress cancer research.Learn more about Dr. Joe Zundellhttps://www.instagram.com/dr.joezundell/Join the Facebook community!Are you a new fitness entrepreneur looking to attract clients? Maybe you're looking to dial in your messaging? Or perhaps you're xperienced and looking to scale your business?Head on over to Facebook, and request access to my Online Marketing for Fitness Professionals group. Post an introduction about yourself, ask some questions, or let us celebrate your wins with you.BSimpsonFitness Best Next Steps:Want to scale to consistent and predictable 20k months without adding more hours to your already packed schedule. Let me show you how for freeSimple Scaling - Want the fastest most efficient way to start and scale a profitable business in the health and wellness space, with less than 2k followers or DMing 100 cold people a day? Watch this short free training and I'll show you how for free. Tap here to register:  https://www.ptprofitformula.com/simplescalingConversion Content Framework - Turn your content into clients without pressure or sleaze even with a small following.90 Days of Done for You Content that Converts:Your shortcut to create compelling content that sets you apart in the fitness industry without sacrificing your authentic voice, and gets your ideal clients excited to work with you without being pushy or sleazy.The Complete 10k Per Month Blue Print - FREEhttps://ptprofitformula.com/your-10k-blueprint This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit beverleysimpson.substack.com/subscribe

In this episode The Wistar Institute's podcast, we take a deep dive with Dr. Luis Montaner, one of Wistar's longest-serving scientists. Listen today as he discusses his lab's groundbreaking HIV cure research and how he decided to dedicate his life to the cause of searching for an HIV cure.

Dr. Maureen Murphy is a Professor and Program Leader in the Molecular and Cellular Oncogenesis Program of the Wistar Institute Cancer Center in Philadelphia. She is also the Associate Vice president for Faculty Affairs and Associate Director For Education and Career Development there. Maureen's research is aimed at understanding and developing cures for cancer. Specifically, they focus on the p53 tumor suppressor protein that is responsible for stopping tumors from forming. When she's not in the lab, you can find Maureen hiking outside with her dogs. She loves nature and thinks dogs are wonderful for reminding us to take a break from our hectic schedules to enjoy life. Maureen is also a fan of traveling, cycling, and yoga. Maureen received her B.S. in biochemistry from Rutgers University and a Ph.D. in molecular biology from the University of Pennsylvania School of Medicine. After graduate school, she completed postdoctoral research at Princeton University. Maureen served on the faculty at the Fox Chase Cancer Center before accepting her current position at the Wistar Institute. Maureen is with us today to tell us all about her journey through life and science.

This episode is brought to you by Cozy Earth, Lifeforce, and Lumebox.Despite significant strides in cancer research over the past two decades, there remains a vast realm of uncertainty surrounding the impact of various cancers on individuals. Amidst the proliferation of cancer discourse on social media, distinguishing evidence-based information from conjecture can prove challenging. Today's guest is here to untangle all the complexities. Today, on The Dhru Purohit Show, Dhru sits down with Dr. Joseph Zundell to discuss the research behind cancer prevention. Dr. Zundell shares the lifestyle factors that influence the development of cancer and the cutting-edge technologies for early cancer detection. Dr. Joe Zundell received his Ph.D. in cancer biology through the University of the Sciences and The Wistar Institute in Philadelphia, PA. He has over ten years of cancer research experience as a cancer biologist. Much of his published research has focused on finding new therapies for the treatment of many different cancer types based on the epigenetic and metabolic characteristics of cancers. In this episode, Dhru and Dr. Zundell dive into (audio version / Apple Subscriber version):Technology for early detection of cancer (4:55 / 4:55)Obesity and visceral fats link to cancer (22:56 /19:30)Exercising to build muscle and for longevity (28:57 / 25:06)Protein intake and the metabolic process (35:00 / 30:23)Fasting mimicking diet before chemotherapy (47:14 / 42:17)Otto Werberg's research (53:17 / 49:39)Cancer as a metabolic disease (58:15 / 53:40)An overview of Dr. Thomas Seyfried's work and Dr. Zundell's viewpoint (1:07:07 / 1:02:08)Dr. Zundell's views on what needs additional research (1:09:43 / 1:05:09)Dr. Zundell's origin story (1:18:54 / 1:13:00)Socioeconomic status and its impact on disease (1:30:37/ 1:26:38)Rapid fire community questions (1:34:02 / 1:28:35)Also mentioned in this episode:Dr. Zundell's research Get $300 off Prenuvo at prenuvo.com/dhru (not an affiliate link)Ezra Test Fasting and Caloric Restriction in Cancer Prevention and TreatmentProfessor Valter Longo's Study Right now, get 40% off your Cozy Earth sheets. Just head over to cozyearth.com and use code DHRUP.Right now, you can save $250 on your first diagnostic and get personalized suggestions. Optimize your longevity and track your progress go to mylifeforce.com/dhru! Lumebox is offering my community $260 off their FDA-approved portable Red Light device! That's over 50% off! Go to thelumebox.com/dhru and get your Red Light device. Hosted on Acast. See acast.com/privacy for more information.

BUFFALO, NY- October 30, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on March 24, 2023, entitled, “Neutrophil PAD4: how does it function in cancer beyond promoting NETosis?” Expansion of pathologically activated immune suppressive myeloid cells called myeloid-derived suppressor cells (MDSC) is one of the hallmarks of cancer. In most tumor types, MDSC are represented primarily by pathologically activated neutrophils (PMN-MDSC). In this new editorial, researchers Laura Garcia-Gerique and Yulia Nefedova from the Wistar Institute discussed their team's recent study identifying a novel mechanism by which neutrophil PAD4 promotes cancer progression. “Using several transplantable and genetically engineered mouse models, we demonstrated that tumor growth was accompanied by significantly elevated enzymatic activity of neutrophil PAD4 [10]. To further clarify the role of PAD4 in tumor progression, we utilized PAD4fl/fl MRP8Cre mice with targeted deletion of PAD4 in myeloid cells, primarily neutrophils.” PMN-MDSC originate in the bone marrow and migrate to various sites including tumor tissues and premetastatic niches. These cells have a relatively short lifespan (less than 48 hours) and, therefore, are continually replaced from the bone marrow. Tumor-infiltrating PMN-MDSC possess a potent suppressive activity as they are able to inhibit both antigen-specific immune responses of T cells and non-specific anti-CD3/CD28-stimulated responses. As a result, a highly immunosuppressive environment is created in tumors, which prevents their rejection via immunological mechanisms. In addition, PMN-MDSC employ non-immunological mechanisms to facilitate tumor progression, including angiogenesis, remodeling of extracellular matrix, and production of cytokines. In patients with solid tumors, levels of MDSC in circulation and tumor tissues have been positively associated with a poor response to the therapy in many types of cancer and represent an independent indicator of poor outcomes. However, many of the details about how PMN-MDSC support cancer progression, and thus approaches for therapeutically targeting these cells, remain enigmatic. “Taken together, our study identified a new mechanism responsible for transcriptional regulation of neutrophil migration and a new mechanism by which neutrophil PAD4 is contributing to tumor progression. PAD4 inhibitors are in development and may enter early phase clinical trials in the future.” DOI - https://doi.org/10.18632/oncotarget.28369 Correspondence to - Yulia Nefedova - ynefedova@wistar.org Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28369 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PAD4, PMN-MDSC, neutrophils, neutrophil migration About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Alex Valiga is the current chief resident physician in the Department of Dermatology and Cutaneous Biology here at Thomas Jefferson University. He grew up outside of Philadelphia in North Wales, Pennsylvania and attended nearby Drexel University where he earned a bachelor's degree in biomedical engineering. It was during this time that Dr. Valiga developed his passion for cutaneous oncology by spending several years conducting basic science research at the world-renowned Wistar Institute. Given his achievements in academics and research, Dr. Valiga was elected to national honors societies for engineering (Tau Beta Pi) and biomedical engineering (Alpha Eta Mu Beta). After completing his undergraduate studies, Dr. Valiga then continued on to Drexel University College of Medicine. During this time he was honored to be elected co-president of his medical school class for four consecutive years and received the Joel Roslyn Award, an honor reserved for a single member of the graduating class in recognition of outstanding leadership while demonstrating a notable level of commitment and service to his fellow classmates. After graduation, Dr. Valiga then completed an internship in internal medicine at Lankenau Medical Center and is now halfway through his final year of dermatology residency at Thomas Jefferson where he is also serving as Chief Resident. With his academic interests in cutaneous oncology, Dr. Valiga will continue his training with a fellowship in micrographic surgery and dermatologic oncology after which he hopes to continue his career in academic medicine.___0:00 - Intro1:18 - Statistics About Dermatology4:14 - What Is Dermatology?6:36 - Journey Into Dermatology12:56 - 1st and 2nd Years of Dermatology Residency17:55 - Monkeypox Case22:49 - 3rd Year and Overall Residency Experience32:11 - An Average Week of a Dermatology Resident36:28 - Types of Fellowships37:36 - What Fellowship Did You Pick and Why?42:18 - Future of Your Career43:56 - Dealing With Burnout and Keeping a Good Lifestyle50:52 - Maximizing Competitiveness Going Into Derm Residency59:25 - Best Thing About Being a Dermatologist1:00:20 - Worst Thing About Being a Dermatologist1:03:24 - If I Give You $100 Million, What Would You Do?1:08:22 - Future of Dermatology1:10:09 - Advice to People Entering Medicine1:12:10 - Book Recommendations1:15:32 - What Advice Would You Give Your 18-Year-Old Self?1:18:53 - Closing Message for People Looking Into Dermatology1:20:03 - What Makes the Best Dermatology Resident?1:21:17 - Closing Message1:24:41 - Outro__ResourcesI Will Teach You to Be Rich by Ramit Sethi: https://a.co/d/1jQA8D8 Outliers by Malcolm Gladwell: https://a.co/d/hOnFtG8 Man's Search For Meaning by Viktor E. Frankl: https://a.co/d/dHP8ebQ ___View the Show Notes Page for This Episode for a transcript and more information: zhighley.com/podcast___Connect With ZachMain YouTube: @ZachHighley Newsletter: https://zhighley.com/newsletter/Instagram: https://www.instagram.com/zachhighley/?hl=enWebsite: https://zhighley.comTwitter: https://twitter.com/zachhighleyLinkedln: https://www.linkedin.com/in/zach-highley-gergel-44763766/Business Inquiries: zachhighley@nebula.tv___Listen for FreeSpotify: https://open.spotify.com/show/23TvJdEBAJuW5WY1QHEc6A?si=cf65ae0abbaf46a4Apple Podcast: https://podcasts.apple.com/us/podcast/the-zach-highley-show/id1666374777___Welcome to the Zach Highley Show, where we discuss personal growth and medicine to figure out how to improve our lives. My name is Zach a Resident Physician in Boston. Throughout these episodes, I'll interview top performers from around the world in business, life, and medicine in hopes of extracting the resources and techniques they use to get to the top.The best way to help the show is to share episodes on any platform. If you think a friend or family member will like a certain episode, send it to them!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

ENA Respiratory ( https://enarespiratory.com/ ) is a clinical-stage pharmaceutical company developing innate immune modulators for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants. ENA Respiratory is based in Melbourne and Sydney, Australia Dr. Ruth Tal-Singer, Ph.D., Medicine Development Leader, ENA Respiratory, is an internationally recognized healthcare leader and clinical scientist with extensive Research and Development experience including recent roles as Vice President of Respiratory Medical Innovation R&D Value Evidence & Outcomes and Senior Fellow at GSK Pharmaceuticals where during her career she led many projects that resulted in new insights, bringing new treatments to the market. She also formerly served as Chief scientific officer and CEO of the COPD Foundation, where she led the patient-centered research, education, and global community outreach advocacy organization focused on the prevention and early diagnosis and treatment of chronic lung diseases. Her vision led to the creation of World Bronchiectasis Day, observed on July 1. Dr. Tal-Singer's idea resulted in global awareness of the under-researched and under-represented bronchiectasis disease in partnership with 20 other global patient advocacy, academic, and research organizations. As the leader of COPD360Net, the COPD Foundation's digital health, medical devices, and therapeutics development accelerator network, she championed the partnership between ENA Respiratory and the COPD Foundation and served as a member of its Board of Directors on behalf of the COPD Foundation until March 31, 2023. Dr. Tal-Singer has a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. As a researcher, Dr. Tal-Singer has authored 180+ peer-reviewed papers including highly cited scientific publications. She has a Doctor of Philosophy (PhD), Molecular Biology / Microbiology, from University of Pennsylvania, did post-doctoral work at the Wistar Institute, and continues to lecture at the Institute of Translational Medicine and Therapeutics at Penn. Dr. Scott M. White, M.D., Chief Medical Officer, ENA Respiratory, is an infectious diseases physician who has spent over 17 years working in the pharmaceutical and biotech industry. Most recently he served as Vice President Clinical Development for the infectious diseases therapeutic area of Inovio Pharmaceuticals where he was responsible for the clinical development of immunotherapeutic and prophylactic DNA-based vaccines. Prior to this he was a Physician Project Leader for GlaxoSmithKline. In this role he was accountable for several development programs spanning pre-candidate selection through early stage clinical development of assets in the therapeutic areas of infectious diseases, hematology, and dermatology. During this time at GlaxoSmithKline, in collaboration with AstraZeneca, the EU Innovative Medicines Initiative, and medical and scientific leaders throughout Europe, he led the establishment of COMBACTE; a European antibacterial clinical trial network supporting the development of antibiotics targeting resistant organisms.  Dr. White has his M.D. from Pennsylvania State University College, and did an Infectious Diseases Fellowship at University of Pittsburgh School of Medicine. Support the show

After the COVID vaccine rolled out less than a year after the pandemic was first announced, we wondered about progress on a similar front: how close are we to creating an HIV vaccine? What do scientists know about HIV? And what did COVID teach us about immunization? Dr. Amelia Escolano is an assistant professor at the Wistar Institute in Philadelphia. She talks about the intricacies of the HIV virus and what goes into developing an HIV vaccine. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

For many of us in our industry, the reason we do what we do may be because of something that happened within our own lives. For Dr. Joe Zundell, he was greatly impacted by the cancer diagnosis his mom received. Joe takes us through what we should be considering in our programming and coaching style when we're working with people who are battling cancer. His research is extensive and will evidently help the many many people impacted by cancer to have a greater understanding of how to help more people. You're really going to want to tune into this episode.   Don't forget to leave a review on Apple Podcasts. You can also rate 5 stars on Spotify!About Today's Guest  Dr. Joe Zundell received his PhD in cancer biology through the University of the Sciences and The Wistar Institute in Philadelphia, PA. As a cancer biologist he has over 10 years of cancer research experience. Much of his published research has focused on finding new therapies for the treatment of many different cancer types upon epigenetic and metabolic characteristics of cancers. Currently, he is a Research Scientist at a biotherapeutic company near Philadelphia where he is examining Immunotherapies for treating cancers. Joe aims to develop and characterize therapies to enhance cancer patient outcomes. Secondly, he aims to produce educational tools to enable better scientific understanding and instructing. Thirdly, and lastly, he aims to have his own lab with his own projects to progress cancer research.Learn more about Dr. Joe Zundellhttps://www.instagram.com/dr.joezundell/Join the Facebook community!Are you a new fitness entrepreneur looking to attract clients? Maybe you're looking to dial in your messaging? Or perhaps you're experienced and looking to scale your business?Head on over to Facebook, and request access to my Online Marketing for Fitness Professionals group. Post an introduction about yourself, ask some questions, or let us celebrate your wins with you.BSimpsonFitnessLinks & Coaching OpportunitiesPT Profit Formula Jumpstart - a step-by-step proven process to generate consistent 10k Months in 30 Days with just a handful of followers and without sleazy sales.https://www.bsimpsonfitness.com/membership/PT Profit Accelerator - A 6 month coaching intensive designed to take you by the hand and scale to multiple 6 figures and beyond.https://www.bsimpsonfitness.com/accelerator/The Complete 10k Per Month Blue Print - FREEhttps://www.bsimpsonfitness.com/10kblueprint/ This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit beverleysimpson.substack.com

Dr. Joe Zundell received his PhD in cancer biology through the University of the Sciences and The Wistar Institute in Philadelphia, PA. As a cancer biologist he has over 10 years of cancer research experience. Much of his published research has focused on finding new therapies for the treatment of many different cancer types upon epigenetic and metabolic characteristics of cancers. Currently, he is a Research Scientist at a biotherapeutic company near Philadelphia where he is examining Immunotherapies for treating cancers. Joe aims to develop and characterize therapies to enhance cancer patient outcomes. Secondly, he aims to produce educational tools to enable better scientific understanding and instructing. Thirdly, and lastly, he aims to have his own lab with his own projects to progress cancer research.In this episode we discuss:What causes cancer.How can you lower your risk of cancer?The food and lifestyle practices that actually make a difference.Can supplements prevent cancer? Mentioned in this episode:Inside Tracker 20% Off the Entire Storehttps://info.insidetracker.com/drlyonVisit 1st Phorm Website for Free Shippinghttp://www.1stphorm.com/drlyon10% off your first month of online therapy with BetterHelphttps://betterhelp.com/drlyon10% off your first order of Mitopurehttps://timelinenutrition.com/DRLYON

Dr. Stanley Plotkin, MD ( https://en.wikipedia.org/wiki/Stanley_Plotkin ), is an American physician, scientist, and scholar, who in the 1960s, while working at Wistar Institute in Philadelphia, played a pivotal role in discovery of a vaccine against rubella virus (which is now used worldwide as a key component of the MMR vaccine), and has worked extensively on the development and application of a wide range of other vaccines including those for polio, rabies, varicella, rotavirus and cytomegalovirus ( https://www.epiv.eu/ ). Dr. Plotkin graduated from New York University in 1952 and obtained a medical degree at Downstate Medical Center in Brooklyn. He was a resident in pediatrics at the Children's Hospital of Philadelphia and at the Hospital for Sick Children in London. In 1957, Dr. Plotkin served in the Epidemic Intelligence Service of the Centers for Disease Control (CDC) of the U.S. Public Health Service for three years and then served as a member of Wistar's active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, Dr. Plotkin is emeritus professor of Pediatrics at the University of Pennsylvania ( https://www.med.upenn.edu/apps/faculty/index.php/g275/p1554 ), and works as a consultant advising vaccine manufacturers, biotechnology firms, non-profits and governments. Dr. Plotkin's book, Vaccines, remains the standard reference on the subject. He is also an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiology in Washington, D.C. Support the show

Welcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Epigenetics of the mammalian germline, published by Metacelsus on December 23, 2022 on LessWrong. This is a crosspost from my Substack and is is Part 2 of my epigenetics post series. Part 1 is here. The year was 1984, and scientists were wondering: why is sperm, and not just eggs, necessary to make a baby mouse? In non-mammalian species (notably several reptiles), unfertilized eggs can activate as if they were fertilized, copy their genomes, and produce viable offspring. This process is known as parthenogenesis, and scientists could induce it experimentally in mouse eggs, with one research group even reporting live offspring. But as other researchers tried it, it became clear that although parthenogenetic embryos developed to the blastocyst stage, they did not successfully grow to term, and in particular showed defects in the extra-embryonic tissues such as the placenta. Three labs, led by Azim Surani at Cambridge, Davor Solter at the Wistar Institute, and Robin Lovell-Badge at University College London, were hard at work trying to understand why. One hypothesis was that there was some necessary component missing from the egg cytoplasm which the sperm provided. But this was quickly ruled out, because when both the male and the female pronucleus were transplanted from normally fertilized eggs into enucleated recipient eggs, the resulting embryos developed normally. So what was going on? Around the same time, the Surani and Solter labs performed basically the same experiment: Take fertilized eggs and remove either the male or the female pronucleus using a tiny glass needle. Transplant a new male or female pronucleus into each egg, generating eggs with two male pronuclei, two female pronuclei, or one of each (as a control). See how the resulting embryos developed. Both of these research groups came to the same conclusion: the only embryos that developed to term were ones containing both a male and a female pronucleus. These experiments were performed using inbred mouse lines, in which an X-bearing sperm is genetically identical to an egg. So, proper development required some characteristic that was associated with the male-derived and female-derived chromosomes, but was not related to their sequences. Hmm, sounds like epigenetics. This result led Azim Surani to remark: Our studies suggest that specific imprinting of the genome during gametogenesis is essential for full-term development in the mouse. At some point during embryonic development and formation of primordial germ cells, previous influences on the genome are presumably lost and new ones initiated during the production of gametes. This was a remarkable conclusion to make in 1984, but it turned out to be entirely correct. Epigenetic imprinting By “imprinting”, Surani meant the phenomenon where some genes are expressed from only one parent's copy. For example, the IGF2 gene we looked at last time is expressed only from the father's copy, not the mother's. Other genes such as UBE3A follow the opposite pattern, being expressed only from the mother's copy. In 1984, the mechanism of imprinting was unknown, but it turned out to be mediated by DNA methylation. The promoters of certain genes contain imprinting control regions that regulate gene expression depending on their methylation status, which differs between eggs and sperm. In humans there are about 100 known imprinted protein-coding genes, out of a total of about 20,000. As Surani noted, in order for imprinting to work, the parents' imprinting marks need to be lost in the precursors of eggs or sperm, and sex-specific marks need to be written. Let's take a closer look at how this is accomplished. The cycle of the mammalian germline Everything starts when a sperm fertilizes an egg, forming a zygote. The zygote undergoes a rapid series of cell divisions, forming a ...

Link to original articleWelcome to The Nonlinear Library, where we use Text-to-Speech software to convert the best writing from the Rationalist and EA communities into audio. This is: Epigenetics of the mammalian germline, published by Metacelsus on December 23, 2022 on LessWrong. This is a crosspost from my Substack and is is Part 2 of my epigenetics post series. Part 1 is here. The year was 1984, and scientists were wondering: why is sperm, and not just eggs, necessary to make a baby mouse? In non-mammalian species (notably several reptiles), unfertilized eggs can activate as if they were fertilized, copy their genomes, and produce viable offspring. This process is known as parthenogenesis, and scientists could induce it experimentally in mouse eggs, with one research group even reporting live offspring. But as other researchers tried it, it became clear that although parthenogenetic embryos developed to the blastocyst stage, they did not successfully grow to term, and in particular showed defects in the extra-embryonic tissues such as the placenta. Three labs, led by Azim Surani at Cambridge, Davor Solter at the Wistar Institute, and Robin Lovell-Badge at University College London, were hard at work trying to understand why. One hypothesis was that there was some necessary component missing from the egg cytoplasm which the sperm provided. But this was quickly ruled out, because when both the male and the female pronucleus were transplanted from normally fertilized eggs into enucleated recipient eggs, the resulting embryos developed normally. So what was going on? Around the same time, the Surani and Solter labs performed basically the same experiment: Take fertilized eggs and remove either the male or the female pronucleus using a tiny glass needle. Transplant a new male or female pronucleus into each egg, generating eggs with two male pronuclei, two female pronuclei, or one of each (as a control). See how the resulting embryos developed. Both of these research groups came to the same conclusion: the only embryos that developed to term were ones containing both a male and a female pronucleus. These experiments were performed using inbred mouse lines, in which an X-bearing sperm is genetically identical to an egg. So, proper development required some characteristic that was associated with the male-derived and female-derived chromosomes, but was not related to their sequences. Hmm, sounds like epigenetics. This result led Azim Surani to remark: Our studies suggest that specific imprinting of the genome during gametogenesis is essential for full-term development in the mouse. At some point during embryonic development and formation of primordial germ cells, previous influences on the genome are presumably lost and new ones initiated during the production of gametes. This was a remarkable conclusion to make in 1984, but it turned out to be entirely correct. Epigenetic imprinting By “imprinting”, Surani meant the phenomenon where some genes are expressed from only one parent's copy. For example, the IGF2 gene we looked at last time is expressed only from the father's copy, not the mother's. Other genes such as UBE3A follow the opposite pattern, being expressed only from the mother's copy. In 1984, the mechanism of imprinting was unknown, but it turned out to be mediated by DNA methylation. The promoters of certain genes contain imprinting control regions that regulate gene expression depending on their methylation status, which differs between eggs and sperm. In humans there are about 100 known imprinted protein-coding genes, out of a total of about 20,000. As Surani noted, in order for imprinting to work, the parents' imprinting marks need to be lost in the precursors of eggs or sperm, and sex-specific marks need to be written. Let's take a closer look at how this is accomplished. The cycle of the mammalian germline Everything starts when a sperm fertilizes an egg, forming a zygote. The zygote undergoes a rapid series of cell divisions, forming a ...

This week, we talk with Ashani Weeraratna about her inspiring path from apartheid South Africa to director, professor and activist. Ashi cites good advice that she remembers “ read voraciously … and be engaged with the literature”She insists that mentoring is all about the trainees and hearing their individual needsAshi believes that diversity of thought needs diversity of population and stresses the importance of welcoming different groups into the labFor her, representation matters and it is key to achieving full equityShe also comments on the importance of the microenvironment (for cancer cells and for researchers)She shares her thoughts about juggling a life in two citiesAnd she encourages us to remember that “the most important trait is kindness”And Ashi concludes by telling us to enjoy the journeyShe mentioned these institutions, people and resourcesSt. Mary's College of Maryland : https://en.wikipedia.org/wiki/St._Mary%27s_College_of_MarylandGeorge Washington University : https://www.gwu.edu/Johns Hopkins Sidney Kimmel Comprehensive Cancer Center : https://www.hopkinsmedicine.org/kimmel_cancer_center/National Institutes of Health : https://www.nih.gov/Wistar Institute : https://wistar.org/University of Pennsylvania : https://www.upenn.edu/Johns Hopkins Bloomberg School of Public Health : https://publichealth.jhu.edu/National Cancer Institute : https://www.cancer.gov/Steven Patierno : https://medicine.duke.edu/profile/steven-patiernoJeff Trent : https://www.tgen.org/faculty-profiles/jeffrey-trent/National Cancer Advisory Board : https://deainfo.nci.nih.gov/advisory/ncab/ncab.htmTo find out more about Ashi visit her websites or follow her on Twitterhttps://publichealth.jhu.edu/faculty/3918/ashani-t-weeraratnahttps://www.hopkinsmedicine.org/profiles/details/ashani-weeraratnahttps://research.jhu.edu/members/ashani-weeraratna/https://en.wikipedia.org/wiki/Ashani_Weeraratnaon Twitter : @AshaniTW“Is Cancer Inevitable?” by Ashi : https://www.press.jhu.edu/books/title/12767/cancer-inevitableTo find out more about Renaud :Twitter : https://twitter.com/LePourpreLinkedIn : https://www.linkedin.com/in/renaudpourpre/To find out more about Jonathan :Twitter : https://twitter.com/EpigenetiqueLinkedIn : https://www.linkedin.com/in/jonathanweitzman/%20To learn more about the soundtrack :Music by Amaria - Lovely Swindlerhttps://soundcloud.com/amariamusique/https://twitter.com/amariamusique

In honor of National Hispanic Heritage Month, AHLA has partnered with the Hispanic National Bar Association to present this three-part series highlighting the career journeys of Latino/Latina health law leaders. In the third episode, Gelvina Rodriguez Stevenson, Vice President, General Counsel, The Wistar Institute, and Esteban Rodriguez, Counsel, O'Melveny & Myers LLP, speak with Lisa Pino, Former Director, Office for Civil Rights, U.S. Department of Health and Human Services. Prior to that role, Lisa served as the New York State Department of Health's Executive Deputy Commissioner, where she led New York's operational response to the COVID-19 pandemic, and she also served as Senior Counselor at the U.S. Department of Homeland Security.

In honor of National Hispanic Heritage Month, AHLA has partnered with the Hispanic National Bar Association to present this three-part series highlighting the career journeys of Latino/Latina health law leaders. In the second episode, Gelvina Rodriguez Stevenson, Vice President, General Counsel, The Wistar Institute, and Esteban Rodriguez, Counsel, O'Melveny & Myers LLP, speak with Jorge Lopez, Executive Vice President & General Counsel, Memorial Sloan Kettering Cancer Center. Prior to that role, Jorge was head of Akin Gump Strauss Hauer & Field's health care and life sciences practice and served as a legal advisor to Bill Clinton's presidential campaign from 1991-1992.

In honor of National Hispanic Heritage Month, AHLA has partnered with the Hispanic National Bar Association to present this three-part series highlighting the career journeys of Latino/Latina health law leaders. In the first episode, Gelvina Rodriguez Stevenson, Vice President, General Counsel, The Wistar Institute, and Esteban Rodriguez, Counsel, O'Melveny & Myers LLP, speak with Sarina Rivera, Assistant General Counsel, Genentech. In her role, Sarina has provided strategic health care and FDA regulatory counseling to global and U.S. R&D organizations, and she currently supports Genentech's pharmaceutical technical group and is active in the organization's diversity and inclusion initiatives.

Dr. Ashani Weeraratna, Ph.D., (https://publichealth.jhu.edu/faculty/3918/ashani-t-weeraratna) is Bloomberg Distinguished Professor, Chair, Biochemistry & Molecular Biology, and Professor, Johns Hopkins Bloomberg School of Public Health. Dr. Weeraratna is also a recently appointed member (by President Joe Biden), of the National Cancer Advisory Board (https://deainfo.nci.nih.gov/advisory/ncab/ncab.htm), which advises and assists the director of the National Cancer Institute on the activities of the national cancer program. Dr. Weeraratna is a groundbreaking researcher exploring crucial questions about the role aging plays in cancer and her findings on age-related differences in responses to both targeted therapy and immuno-therapy for cancer are leading to a change in clinical practice. Dr. Weeraratna studies the molecular mechanisms involved in metastasis and how tumor micro-environments affect melanoma progression and therapy resistance. She is interested in how the aging micro-environment guides changes leading to increased metastasis and therapy resistance, as well as cell-autonomous aspects of therapy resistance. Dr. Weeraratna's research also encompasses biophysical changes that affect the ability of both tumor and immune cells to migrate. She has demonstrated that normal age-related changes in the micro-environment can contribute to multiple aspects of melanoma formation and development as well as therapy resistance. Dr. Weeraratna's work in melanoma prevention includes a public health approach. She recently helped lead a campaign to introduce sunblock dispensers throughout Philadelphia and talk to children about the dangers of tanning. Dr. Weeraratna is also the author of Is Cancer Inevitable? which clearly describes cancer's mechanisms and how teams like hers are finding ways to reduce its deadly impacts. The book is part of the Johns Hopkins Wavelengths series. Dr. Weeraratna joined Johns Hopkins University as a Bloomberg Distinguished Professor in 2019 from the Wistar Institute where she established her lab back in 2011, and prior to that was at the National Institute on Aging, since 2003. Dr. Weeraratna earned a doctorate in Molecular and Cellular Oncology from George Washington University Medical Center and completed post-graduate training and was a postdoctoral fellow in experimental therapeutics and pharmacology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, then known as the Johns Hopkins Oncology Center. 

Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including - Director of the Vaccine Education Center at Children's Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work. Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.

In this episode—which is for a scientific audience until the 27-minute mark—a current American Cancer Society grantee and a former grantee spoke with each other about their recently published new findings in cancer research. Alessandro Gardini, PhD, an Assistant Professor at The Wistar Institute, studies the epigenetic control of transcription during cell differentiation and oncogenesis. He recently published work in Cell titled “The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer:” https://pubmed.ncbi.nlm.nih.gov/34004147/. Yuan He, PhD, is Assistant Professor (but just received word that he's being promoted to Associate Professor!!) at Northwestern University. The He lab The He lab uses cryo-electron microscopy (cryo-EM) and other biophysical and biochemical approaches to understand “the molecular mechanisms by which large, multi-subunit complexes engage in DNA-centric processes.” Dr. He recently published findings in Science on, “Structure of the human Mediator-bound transcription preinitiation complex:” https://science.sciencemag.org/content/372/6537/52. 4:12 – Dr. Gardini describes his new paper: “what we found is that when you combine CDK9 inhibition with activation by small molecules of the PP2A phosphatase…we get a much better block on transcription in these tumors…” 9:10 – Interesting question from Dr. He on the mysterious integrator complex 11:11 – “What do you think about this tug of war of the phosphatase competing with CDKs…?” 14:19 – Dr. He shared takeaways from his new paper: “And this eventually allowed us to build a model of how this gigantic 57-sub-unit machinery recognized CTD from the polymerase…” 19:11 – Dr. Gardini professes his love for CTD 20:39 – “What do you think is the threshold of phosphorylation in order for the mediator to start losing affinity…?” 25:36 – “Could we possibly think that both mediator and integrator are actually bound to non-phosphorylated CTD at the same time or could there actually be competition…?” 27:46 – Why is this work important? Why should a cancer patient, survivor, or caregiver be excited about these publications?

Today on the Biohack Your Pets Podcast we have Dr. Jeff Feinman. Jeffrey Feinman, BA, VMD, CVH, holds both molecular biology and veterinary degrees from the University of Pennsylvania. Dr. Jeff was the first dual degree recipient at Penn in the prestigious University Scholar program (which was designed to foster medical scientists). His scientific experience includes research at The Wistar Institute, Penn's School of Medicine in the Department of Biochemistry (where he first published his scientific research) and the veterinary school's Department of Medical Genetics (where he wrote further scientific articles). In addition his academic career during veterinary school included an externship in endocrinology at the Animal Medical Center in New York City where he was again published in a leading, peer-reviewed veterinary journal. After graduation from veterinary school, Dr. Jeff was selected for a competitive internship in clinical medicine at the Angell Memorial Animal Hospital in Boston. After fourteen months of intensive clinical experience he decided to postpone his planned academic career to help individual patients. In clinical practice he quickly became alarmed by increasing rates of allergy, cancer and other degenerative diseases. Frustration with the results of conventional therapy of these chronic diseases fueled an interest in natural, holistically-applied therapies. Some patients however were still not responding fully to holistic treatment. Dr. Jeff then applied the principles learned during his molecular biology training to further explore even more effective treatments.  Clinical nutrition, supplementation, herbal therapy, minimal vaccination, etc. were just not enough.  This led him to homeopathy's equisite success in treating otherwise fatal epidemics.  After much reading and some experimentation with the effects of homeopathic drugs (“remedies”) on himself and his pets, he began to incorporate them into his practice. In 1998 he further advanced his training in Dr. Richard Pitcairn's Professional and Advanced Veterinary Homeopathy Courses. Dr. Jeff then became the first Certified Veterinary Homeopath in the state of Connecticut. He has continued his pursuit of lifelong education by studying with world-renowned homeopaths like David Little, Dr. Paul Herscu, Dr. Andre' Saine, Pratful Vijayakar (“Predictive” Homeopathy), etc. Currently he is focused on helping his patients and clients maintain and regain wellness. This is accomplished by integrating his molecular biology and homeopathy knowledge into a unified method called the Vitality and Balance System (VBS). In addition to researching VBS and learning more every day, Dr. Jeff is devoted to teaching both pet owners and other veterinarians about optimal pet care.  He and his wonderful wife Amy live with Archie and Vanya, who are two rescued pups and a Rex cat named Tigger. He is the Chief Empowerment Officer and founder of Holistic Actions!, Chairman of the Academy of Homeopathy (AVH) Education committee, President of the AVH Foundation, and was previously the holistic medical director for On The Wings Of Angels rescue in Odessa FL, and is helping to mentor other veterinarians.  Currently his practice integrates the latest, safest, diagnostic techniques and treatments with holistic modalities such as clinical nutrition and homeopathy. Member: American Veterinary Medical Association (licensed in Connecticut, California, and Florida) Founder and CEO of Holistic Actions! President of The Academy of Veterinary Homeopathy (AVH) Foundation Past president of AVH Chairman of the AVH Education Committee CT's First Certified Veterinary Homeopath: 2000 Veterinary Honor Society (Phi Zeta): Inducted 1985 University Scholar: Inducted 1980 Dr. Jeff Feinmans Website Today's topics include: 3:44 - Background  7:35 - Getting into homeopathy 9:51 - How does homeopathy interact with the cell membranes 12:11 - First step to affect vitality of patient 17:06 - What is whole food 20:55 - B.E.A.M. Symptoms 23:00 - What if nutrition isn't enough 31:00 - Our feelings affect our pets 38:15 - What about Cats? 43:59 - Where can we find you and how can people work with you   https://www.holisticactions.com/terrain/   https://www.holisticactions.com/susceptibility/   https://www.holisticactions.com/happiness-protocol/?amp   The 3 take-home benefits:   1. Significance of symptoms (aka "signs”) 2. Focusing on BEAM and quality of life(vs. individual symptoms or dis-eases) 3. The Happiness Protocol and holistic actions to help pets flow

 Dr. Jamie L. Wells, MD, FAAP, is an Adjunct Professor at Drexel University's School of Biomedical Engineering, Science and Health Systems, where she has been involved in helping to spearhead the nation's first-degree program focused on pediatric engineering, innovation, and medical advancement. She just co-authored an article in the journal Artificial Organs on this newly emerging applied science. Dr. Wells is an award-winning Board-certified pediatrician with many years of experience caring for patients. With her BA with Honors from Yale, and her MD from Jefferson Medical College, Philadelphia, PA, where she was President of the Alpha Omega Alpha National Medical Honor Society, she has served as a Clinical Instructor/Attending at NYU Langone, Mt. Sinai-Beth Israel and St. Vincent's Medical Centers in Manhattan. Dr. Wells also serves as Director of the Research Science Institute (RSI), at the Center for Excellence in Education (CEE), a non-profit, 501(c)(3) organization, collaboratively sponsored with MIT which brings together top U.S. and international high school students for an intensive, six-week summer program that provides students with the opportunity to conduct original, cutting-edge research. Dr. Wells is on the leadership council of the Wistar Institute (the USA's first independent biomedical research facility and certified cancer center), an Ambassador in Healthcare for the Global Blockchain Business Council, was a grant reviewer for the Susan G. Komen Community Grants Program, judged both the local, district and world robotics championships for Dean Kamen's F.I.R.S.T. (For Inspiration & Recognition of Science & Technology) nonprofit and is the President and Founder of the Yale Alumni Health Network (YAHN). Dr. Wells has a proven track record of success in communications on various platforms (e.g. BBC, Reuters TV, Fox News Channel, Discovery Health), routinely appearing as a medical expert and has published over 400 articles as director of medicine for an educational advocacy nonprofit. Dr. Wells has broad ranging interests in patient safety and optimizing care delivery, bioethics, public health and policy, science communications, med-tech innovation, diagnosis and management of disease, identifying healthcare trends, bridging interdisciplinary knowledge gaps to prevent medical error and expedite discovery, thought integration of clinical practice and biomedical engineering approaches with an emphasis on patient-centered design, debunking medical myths and pediatrics. 

Dr. Jamie Wells is many things, but boring is not one of them. Prepare yourself for some frenetic genius conversation with the newly-appointed Director of the Research Science Institute (RSI) collaboratively sponsored by the Massachusetts Institute of Technology (MIT) and the Center for Excellence in Education (CEE). What's more, she is on the Leadership Council member of The Wistar Institute, an Advisor to the Global Blockchain Business Council, and an Adjunct Professor at Drexel University's School of Biomedical Engineering. But what's most important about Jaime has nothing to do with any of that because she's a Nickelodeon Double Dare Champion and friend of Marc Sommers. Need I say more? Strap in for a conversation filled with so much IQ that you may need to listen to it backward like a Led Zepplin album for it to make sense. No, but seriously, she's going to blow your mind.Follow us on social media:Out of Patients: @MZOutofPatients on TwitterMatthew Zachary: @MatthewZachary on Twitter & FacebookOffScrip Media: @OffscripMedia on Twitter & Facebook

In today's episode, Chad sits down with guest scientists, Drs. Jolly Mazumdar and Tim Chendrimada, CEO, and CSO of Chimeron Bio. Two different beginnings; one in the sciences studying bugs and infectious diseases and the other in agriculture, specifically coffee beans! They talk to Chad about how their very different paths led them to become a dynamic duo in the next generation of RNA therapeutics. From Tim asking a scientist of Wistar Institute to take a chance on him with no prior experience in medical science to Jolly traveling to the United States for graduate studies in infectious diseases, we learn about how the pair, originally from India, carved their paths to where they are now as veterans in the Pharma industry. Both with careers early on at GlaxoSmithKline (GSK), Jolly’s focus was on biomarkers and innovative early clinical trials in skin cancer drugs and Tim’s on the development side as a bench scientist and the importance of having teamwork when it comes to drug development. These valuable experiences led them to create Chimeron Bio. They talk about how the opportunity to create Chimeron Bio came to be, the importance of challenging yourself and taking risks you believe in, talking to investors, their technology pipeline and self-amplifying RNA COVID-19 vaccine that protects against new variants. See omnystudio.com/listener for privacy information.

This is not the first time scientists have raced to develop vaccines against a new disease.  In the 1960s, scientists faced a similar crisis over rubella, also known as German measles.  Today Mark explores the race to create the rubella vaccine with Dr. Stanley Plotkin, dubbed ‘The Godfather of Vaccines’.  In 1964, working in his Wistar Institute laboratory in Philadelphia, Stanley developed the rubella vaccine — the “R” in MMR— that’s now used across the world.  And Melissa speaks to science writer Meredith Wadman about the ethics of creating the rubella vaccine. Hosted by Mark Honigsbaum @honigsbaum With Dr. Stanley Plotkin, Professor Emeritus at the Wistar Institute and University of Pennsylvania, and consultant to the vaccine industry. vaccinestoday.eu/stories/author/splotkin/ Meredith Wadman @meredithwadman, Reporter @ScienceMagazine, Author of "The Vaccine Race: Science, Politics and the Human Costs of Defeating Disease”. meredithwadman.com   sciencemag.org/news/2020/03/physician-whose-1964-vaccine-beat-back-rubella-working-defeat-new-coronavirus Series Producer: Melissa FitzGerald @Melissafitzg Cover art by Patrick Blower www.blowercartoons.com Follow us on Twitter @GoingViral_pod      Follow us on Instagram: goingviral_thepodcast If you are enjoying our series do leave us a rating or review! Thank you

This is not the first time scientists have raced to develop vaccines against a new disease.  In the 1960s, scientists faced a similar crisis over rubella, also known as German measles.  Today Mark explores the race to create the rubella vaccine with Dr. Stanley Plotkin, dubbed ‘The Godfather of Vaccines’.  In 1964, working in his Wistar Institute laboratory in Philadelphia, Stanley developed the rubella vaccine — the “R” in MMR— that’s now used across the world.  And Melissa speaks to science writer Meredith Wadman about the ethics of creating the rubella vaccine. Hosted by Mark Honigsbaum @honigsbaum With Dr. Stanley Plotkin, Professor Emeritus at the Wistar Institute and University of Pennsylvania, and consultant to the vaccine industry. vaccinestoday.eu/stories/author/splotkin/ Meredith Wadman @meredithwadman, Reporter @ScienceMagazine, Author of "The Vaccine Race: Science, Politics and the Human Costs of Defeating Disease”. meredithwadman.com   sciencemag.org/news/2020/03/physician-whose-1964-vaccine-beat-back-rubella-working-defeat-new-coronavirus Series Producer: Melissa FitzGerald @Melissafitzg Cover art by Patrick Blower www.blowercartoons.com Follow us on Twitter @GoingViral_pod      Follow us on Instagram: goingviral_thepodcast

It is very easy to get lost in the Wister family.  Anyone familiar with Philadelphia History probably knows about Caspar Wistar, who founded the Wistar Institute, and author Owen Wister, who wrote the first Western novel “The Virginian” and is buried at Laurel Hill Cemetery.  But this was a large family.  There are 40 Wisters and 30 Wistars buried at Laurel Hill Cemetery, along with 3 Wisters at West Laurel Hill.  Today I am going to talk about four Wister brothers and one of their sons buried at Laurel Hill Cemetery.  William Rotch Wister was lawyer and founder of the Germantown Cricket club.  John Wister was founder and manager of a major iron works and a bank.  Langhorne Wister was a colonel with the Bucktail Regiment during the Civil War, shot through the mouth at the Battle of Gettysburg.  And Rodman Wister ran away from home to become a drummer boy.  John Caspar Wister, son of William Rotch, was considered the dean of horticulturists in the United States.  Their stories are fascinating and informative.  

Kenneth L. Johnson is the President of East Coast Executives, TEDxHarlem Organizer, TEDx Speaker, Forbes Coach, Google On-Air Facilitator, Host and Executive Programmer of The Career Seekers Show On WPPM 106.5 FM in Philadelphia, PA and Host of Urban League Jobs Network. Kenneth L. Johnson is a distinguished Diversity Recruiter and Executive Search professional with 20 years of experience delivering talent-acquisition solutions. In 2019 Kenneth was selected to facilitate weekly Career Workshops at The Google Learning Center New York City. He is a member of The Forbes Coaches Council and is recognized by Black Enterprise Magazine as a BE Modern Man..  At East Coast Executives, Kenneth drives business results for clients through creative sourcing strategies and global recruiting programs as Founder and President. Kenneth has designed recruiting and sourcing strategies for an esteemed roster of client companies including Tiffany and Co.., New York Life, Disney, Pepsi, UPS, Gordon Foods, Crocs, Fruit of the Loom, JOIN for Justice and The Wistar Institute to recruit diverse talent.  His dedication to innovative talent-acquisition strategies and quality candidates makes him a highly sought-after strategic diversity business partner and consultant. Kenneth currently serves as the Diversity Recruitment Specialist for The New York Urban League and is a Forbes Contributor. He has served on several panels and has been featured in Black Enterprise, INC., Solve Magazine, NY Daily News, Monster.com, Fast Company Magazine, Philly.com and The Philadelphia Business Journal.  Kenneth is the Host and Executive Programmer of The Career Seekers Show on WPPM 106.5 in Philadelphia, PA. You can find Kenneth: Website: East Coast Executives eastcoastexecutives.com   Linkedin: linkedin.com/in/kljohnsoninfo
Email kjohnson@eastcoastexecutives.com Twitter @KLJOHNSONINFO Connect with Lisa Pineda here: Website: www.lisapinedayoga.com TEDx Talks: How Yoga Helped Me to Let Go & How Meditation Can Unlock Your True Potential --- Support this podcast: https://anchor.fm/lisa-pineda/support

 Dr. Leonard Hayflick, is Professor of Anatomy, University of California, San Francisco School of Medicine, where he has been part of the faculty since 1988 Dr. Hayflick received his Ph.D. at the University of Pennsylvania, did a post-doctoral fellowship at the University of Texas under the tutelage of the renowned cell culturist Prof. Charles Pomerat, and then returned to Philadelphia, where he spent ten years as an Associate Member of the Wistar Institute, and two years as an Assistant Professor of Research Medicine at the University of Pennsylvania. Dr. Hayflick is extremely well known for his research in a range of domains including cell biology, virus vaccine development, and mycoplasmology. In 1962 he discovered that, contrary to what was believed since the turn of the century, cultured normal human and animal cells have a limited capacity to replicate. This phenomenon became known as “The Hayflick Limit” which became a discovery that overturned a dogma that existed since early in the twentieth century and focused attention on the cell as the fundamental location of age changes. Dr. Hayflick is a member of numerous national and international scientific and public boards of directors and committees. He is now, or has been, on the Editorial Boards of more than ten professional journals including as Editor-in-Chief of the international journal “EXPERIMENTAL GERONTOLOGY” He is a member of twenty scientific and professional societies in which he has held high offices including President of the Gerontological Society of America, a founding member of the Council of the National Institute on Aging, NIH and Chairman of its' Executive Committee, consultant to the National Cancer Institute, the World Health Organization and member of several scientific advisory boards. He was also Chairman of the Scientific Review Board of the American Federation for Aging Research where he was also a Vice President and a Member of the Board of Directors. Dr. Hayflick is the author of the popular book, “How and Why We Age” and was also a consultant at Genentech from a year after its founding and for the next 25 years where he was instrumental in developing their technology for growing animal cells in fermentation tanks in which most of their billion $$ blockbuster biologics products were produced. 

Scientists in Philadelphia have been working hard on a COVID-19 vaccine at the Wistar Institute at the University of Pennsylvania, in partnership with INOVIO Pharmaceutical. Dr. David Weiner is the Director of the Wistar Institute's Vaccine Center and co-founder of INOVIO. We wanted to check in with him to see what they've learned about the virus, how their vaccine development is going, and to get his take on the vaccines we've heard about in the news that are pretty close to the finish line.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Not even a year after SARS-CoV-2 was first identified, several coronavirus vaccines are now in the final stages of testing. Some people worry we’re moving too fast; others argue that “Operation Warp Speed” is not moving nearly fast enough. There’s a lot at stake — from public health, to trust in science, to the economy — and failure is not an option. On this episode we track the quest for a coronavirus vaccine. We talk with people who’ve received trial vaccines, scientists who are developing their own, and experts about everything from supply chain issues to the ethics of who should be vaccinated first. Also heard on this week’s episode: Creating a vaccine is hard enough — but distribution might be even harder. Reporter Alan Yu explores the challenges of producing and transporting billions of doses of vaccines around the world. Thanks to David Weiner, director of the Vaccine and Immunotherapy Center at the Wistar Institute, for his help with this story. We hear from two people who are volunteering as participants in a phase 3 clinical trial for a coronavirus vaccine — physician and public health expert Chris Pernell, and podcaster and minister Scott Jones. We talk with Paul Offit, an infectious disease physician and co-creator of the rotavirus vaccine, about the process for proving vaccines are safe and effective, as well as some of the missteps and tragic mistakes made in recent history. Legal scholar Govind Persad takes on thorny ethical questions about who should get the vaccine first. We talk with science journalist Olga Dobrovidova about Russia’s coronavirus vaccine — what we know about its efficacy, and why it’s getting the side-eye from the Russian public. We hear from listeners about their hopes and fears about an upcoming vaccine. The people of the Navajo Nation — the largest Native American reservation in the U.S. — have suffered one of the worst COVID-19 death rates of any place in the world. But when the vaccine trials came looking for volunteers, few were willing. Reporter Anthony Wallace explains why.

Dr. Mary Elizabeth speaks with Dr. Stephen Marini, a chiropractor and international lecturer, and serves on the boards of the ICPA, HPA and Intergrative Health Policy Consortium (IHPC). Dr. Marini was educated in basic science and medicine at Hahnemann Medical College in Philadelphia where he received a M.S. in Microbiology and Immunology in 1976. Doctoral studies followed at the University of Pennsylvania and Pacific Western University where he conducted dissertation research on avian tumor viruses accomplished at the Wistar Institute in Philadelphia. He received his Ph.D. in Microbiology in 1989. Dr. Marini received vitalistic training and professional development at the Pennsylvania College of Chiropractic where he received his D.C. in 1988. He received the Diplomate in Chiropractic Pediatrics from the Academy of Chiropractic Family Practice in 2007. He served as professor of Microbiology at the Pennsylvania College of Chiropractic from 1980 until 1995, and as Academic Dean from 1990-1993. As a vitalist trained in classical science and conventional medicine, Dr. Marini appreciates the role of energy/information on an individual's health and healing processes. He recognizes the need for a complementary, patient-centered approach to healing and health care options. Dr. Marini incorporates this knowledge and belief into his teaching of psychoneuroimmunology as well as his practice of chiropractic. He currently practices chiropractic with his son Dr. Nicholas in King of Prussia and Philadelphia, Pennsylvania and lectures internationally on psychoneuroimmunology and vaccination issues. Connect with Dr. Mary Elizabeth: https://mailchi.mp/5dea388e4560/podcast-coaching-calls Connect with Dr. Stephen Marini: motomarini@msn.com --- Support this podcast: https://anchor.fm/mary-elizabeth-me/support

Dr. Stanley Plotkin developed the rubella vaccine for what was commonly called the German measles at the Wistar Institute back in the 1960's.  It helped to eradicate the disease in the United States and has become the R in what is known as the MMR vaccine.  He also worked on vaccines for anthrax, polio, rabies … Continue reading Special Edition 10 Godfather of Vaccines Discusses Race to Protect Against Covid-19

On the PHLCVB Podcast, Dr. Heather Steinman, Vice President for Business Development/Executive Director of Technology Transfer at The Wistar Institute and co-chair of the PHL Life Sciences Advisory Board, discusses the role of PHL Health Advisors. This newly created PHLCVB task force, the only of its kind in the nation, draws from the strength of the Philadelphia region’s renowned scientific and medical community.

Apr 14, 2020In the midst of this COVID-19 pandemic, the question on everyone's mind is when will the social distancing and sheltering at home end? While there may not be a clear cut answer, a step in the right direction is the research and development of a vaccine for the virus. Dario Altieri, MD, the President and CEO of the Wistar Institute, spoke with Abby Melone about his organization's research work towards developing a vaccine and what that has entailed. For more information, visit: For a limited amount of time, register to read all Capital Analytics reports for free: https://www.capitalanalyticsassociate...

Ira Pastor, ideaXme life sciences ambassador, interviews Dr. Stanley Plotkin, Professor Emeritus at both Wistar Institute and the University of Pennsylvania and consultant to the vaccine industry. Ira Pastor Comments: So as we sit here a few months into the global Covid-19 pandemic, one big question on everyone’s mind is when will we see the first mass produced vaccine against this current strain, especially as it looks like in the United States there will be some loosening of quarantine / "shelter in place" rules to re-start the economy. Dr. Stanley Plotkin: Dr. Stanley Plotkin is an American physician, scientist, and scholar, in many circles referred to as “the Godfather of Vaccines", who in the 1960s, while working at Wistar Institute in Philadelphia, played a pivotal role in discovery of a vaccine against Rubella virus (also known as German measles or three-day measles), which is now used worldwide (as a key component of the MMR vaccine - a combination vaccine also that protects against measles and mumps) and has worked extensively on the development and application of a wide range of other vaccines including polio, rabies, varicella, rotavirus and cytomegalovirus. Dr. Plotkin graduated from New York University in 1952 and obtained a medical degree at Downstate Medical Center in Brooklyn. He was a resident in pediatrics at the Children’s Hospital of Philadelphia and at the Hospital for Sick Children in London. In 1957, Dr. Plotkin served in the Epidemic Intelligence Service of the Centers for Disease Control (CDC) of the U.S. Public Health Service for three years, and then served as a member of Wistar’s active research faculty from 1960 to 1991. Today, in addition to his emeritus appointment at Wistar, he is also Professor Emeritus of Pediatrics at the University of Pennsylvania, and works as a consultant to vaccine manufacturers, such as Sanofi Pasteur, as well as biotechnology firms, non-profits and governments. Dr. Plotkin's book, "Vaccines", remains the standard reference on the subject. Dr. Plotkin is also an editor with Clinical and Vaccine Immunology, which is published by the American Society for Microbiology in Washington, D.C. On this episode we will hear from Dr. Plotkin: About his background; how he became interested in medicine, research, and how after joining Wistar (under the equally famous Dr. Hilary Koprowski), and working for a bit with Anthrax, how Rubella became a target of interest, His thoughts on Covid-19: how worried / concerned / optimistic he is about vaccine development. How with dozens of coronavirus vaccine candidates being developed, in various companies and organizations (including RNA vaccines, DNA vaccines, single protein vaccines, multiple protein vaccines, etc.) how a choice is made of which "to go with" once some are approved. About the requirement for a "perfect vaccine" with 100% coverage, versus less perfect vaccines that could get to market earlier. The topics of Plant BioTechnology, edible vaccines and the Anti-Vaccine movement. Credits: Ira Pastor interview video, text, and audio. Follow Ira Pastor on Twitter:@IraSamuelPastor If you liked this interview, be sure to check out ourinterview with Dr. Linfa Wang: Hunting Down Covid-19 and Other Deadly Diseases! Follow ideaXme on Twitter:@ideaxm On Instagram:@ideaxme Find ideaXme across the internet including on iTunes,SoundCloud,Radio Public, YouTube, TuneIn Radio,I Heart Radio, Google Podcasts, Spotify and more. ideaXme is a global podcast, creator series and mentor programme. Our mission: Move the human story forward!™ ideaXme Ltd.

In this episode we'll be speaking with Dr. Stephen Marini about natural immunity and the importance of staying grounded during uncertain circumstances. Stephen Marini, PhD, DC, is a chiropractor and international lecturer, and serves on the boards of the ICPA, HPA and Intergrative Health Policy Consortium (IHPC). Dr. Marini was educated in basic science and medicine at Hahnemann Medical College in Philadelphia where he received a M.S. in Microbiology and Immunology in 1976. Doctoral studies followed at the University of Pennsylvania and Pacific Western University where he conducted dissertation research on avian tumor viruses accomplished at the Wistar Institute in Philadelphia. He received his Ph.D. in Microbiology in 1989. Dr. Marini received vitalistic training and professional development at the Pennsylvania College of Chiropractic where he received his D.C. in 1988. He received the Diplomate in Chiropractic Pediatrics from the Academy of Chiropractic Family Practice in 2007. He served as professor of Microbiology at the Pennsylvania College of Chiropractic from 1980 until 1995, and as Academic Dean from 1990-1993. https://www.marinichiroanded.com

On this episode of Court Radio, Dean Weitzman of MyPhillyLawyer speaks to David B. Weiner, Ph.D., Director of Vaccine & Immunotherapy at the Wistar Institute about the development of the coronavirus vaccine, how vaccines are created, what effects it will have, and answer questions from callers about the coronavirus.

Coronavirus or COVID-19 is rapidly spreading across the globe, and in cities across the United States, hand sanitizer, soap, cleaning wipes and masks are flying off store shelves. With new cases reported every day, health experts are scrambling to learn more about the virus, and government agencies are working to contain it. So what do we actually know about the outbreak, and is Philadelphia prepared? Today on KYW In Depth, Dr. Harvey Rubin, infectious disease specialist at the University of Pennsylvania, Dr. Steven Alles, the Director of Disease Control at Philadelphia's Department of Public Health, and Dr. David Weiner, director of the Wistar Institute's Vaccine and Immunology Center join the podcast to tell us what we need to know and how Philadelphia is going to respond to the virus. 

Dr. David Weiner is Executive Vice President, Director of the Vaccine & Immunotherapy Center, and the W.W. Smith Charitable Trust Professor in Cancer Research at The Wistar Institute. He is also Emeritus Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania. In the lab, David and his colleagues are creating drugs using the same DNA codes and signals that our bodies use naturally. The drugs they are creating are natural compounds that can be given to people to prevent them from getting sick or to help them be healthier. One area of David’s research focuses on developing DNA vaccines to prevent illness. These DNA vaccines are designed to create specific proteins that trigger the immune system to respond to fight particular pathogens. David and his wife enjoy reading and going on walks with their dog Ruby. Ruby is a Shih Tzu Yorkie mix that they rescued after a recent hurricane in Puerto Rico. David received his B.S. in biology from the State University of New York at Stony Brook, his M.S. in biology from the University of Cincinnati, and his  Ph.D. in developmental biology from the University of Cincinnati College of Medicine. Afterwards, David worked as a research fellow in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania before joining the faculty there. He held a joint position as Assistant Professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine from 1990-1993. David returned to The Wistar Institute in 2016 to accept his current positions. Among his many awards and honors, David has been elected as a Fellow of the American Association for the Advancement of Science and the International Society for Vaccines. He has also received the NIH Director’s Transformative Research Award, the Vaccine Industry Excellence Award for Best Academic Research Team, the prestigious Hilleman Lectureship from the Children’s Hospital of Philadelphia, a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy, and the Scientific Achievement Award from Life Sciences Pennsylvania. In addition, David was named a "Top 20 Translational Researchers" in 2016 by Nature Biotechnology.

Today we celebrate the birthday of the English Statesman who created “Garden walks” and the birthday of a man who is remembered by Muhly grass. We'll learn about the man memorialized by a plant name that misspells his last name, and we'll also learn about the disastrous freeze for Florida growers that happened in the mid-1980s. Today’s Unearthed Words feature poetry and quotes that teach the lessons we can learn from winter. We Grow That Garden Library™ with a book that shares terrific essays on the benefits of gardening. I'll talk about a garden item that can definitely come in handy for gardeners, and then we’ll wrap things up with the story of a botanist who recognized that new species can always be discovered, even in areas previously explored. But first, let's catch up on a few recent events.   Subscribe Apple | Google | Spotify | Stitcher | iHeart   Curated Articles The Wardian case: Botany game-changer | Kew From @kewgardens The Wardian case: Botany game-changer: It's incredible to think that the Wardian case was invented by British doctor and amateur naturalist Nathaniel Bagshaw Ward in 1829 by complete accident...   Gardens: Winning ways for winter Oodles of great tips for designing a Winter Garden from Anglesey’s assistant head gardener David Jordan: One of Jordan’s favorite combinations is the shaggy-barked paperbark maple teamed with the variegated evergreen shrub Euonymus fortunei ‘Emerald Gaiety’ and the pink, scented blossoms of Viburnum x bodnantense ‘Dawn.’ At Anglesey, the euonymus is cloud-pruned in summer to create a sinuous shape, but as Jordan points out, “It has adventitious roots, so you could grow it up the walls of a house and have it as a backdrop.” Jordan also recommends the crab apple tree Malus ‘Evereste’ as a centerpiece to a winter border. “You get long, persistent fruit, and you can underplant with dogwood in red or orange that works with the color of the fruit. Underplant with snowdrops, then daffodils, and this takes you through to May when you get the flowers – that gives you a long window of interest.” The winter garden recipe runs something like this: a tree with colorful or tactile bark – try Tibetan cherry (Prunus serrula), paperbark maple (Acer griseum) or Arbutus unedo, the strawberry tree – acts as an anchor for the rest of the planting; then add a mid-level shrub with scented flowers, colored stems or attractive leaves (dogwoods, euonymus, daphnes, viburnums or sarcococcas); finally, there’s the option of a low-growing ground cover (snowdrops and hardy cyclamen, or foliage such as bergenias or pulmonarias).   Now, if you'd like to check out these curated articles for yourself, you're in luck, because I share all of it with the Listener Community in the Free Facebook Group - The Daily Gardener Community. There’s no need to take notes or search for links - the next time you're on Facebook, search for Daily Gardener Community and request to join. I'd love to meet you in the group.   Important Events 1561 Today is the birthday of the English philosopher and statesman Francis Bacon. Francis wrote a splendid essay called “Of Gardens.” The essay contains many quotable thoughts on gardening - although the opening line is the most quoted. “God Almighty first planted a garden. And indeed, it is the purest of human pleasures. It is the greatest refreshment to the spirits of man; without which, buildings and palaces are but gross handiworks; and a man shall ever see, that when ages grow to civility and elegancy, men come to build stately sooner than to garden finely; as if gardening were the greater perfection. I do hold it, in the royal ordering of gardens, there ought to be gardens, for all the months in the year, in which several things of beauty may be then in season.” In 1606, Francis introduced “Garden Walks” as a concept at Gray's Inn field. Bacon lived at Gray’s Inn, and during that time, the Inns were putting gates and fencing around their land to provide greater privacy and security. It was in the gated field at Gray’s Inn where Bacon created his walk. People were enthralled with the idea. Along the walk, Bacon added flowers and trees like Violets and Primroses, Cherry Trees, and Birch. This whole notion of strolling through a pleasure garden was the 16th century equivalent of the modern-day habit of walking in a shopping mall for exercise. In 1594, Francis Bacon said a learned man needs a garden, library, laboratory -- and a "goodly, huge cabinet" (of curiosities). And, Bacon said, "As is the garden - such is the gardener. A man's nature runs either to herbs or weeds."   1785Today is the day the American Lutheran Pastor and botanist Gotthilf Heinrich Ernst Muhlenberg was made a member of the American Philosophical Society. He was always referred to by his second name Heinrich. The Muhlenberg family was a founding family of the United States, and Heinrich came from a long line of pastors. His father, Pastor Heinrich Melchior Mühlenberg, was known as the patriarch of the Lutheran Church in America. His brother was a major in the Revolutionary War, and his other brother was a Congressman. Muhlenberg’s personal journals are a treasure trove of his thoughts on botanical self-improvement. He would write: "How may I best advance myself in the knowledge of plants?” And, Muhlenberg would set goals and reminders to challenge himself, writing: “It is winter, and there is little to do . . . Toward spring I should go out and [put together] a chronology of the trees; how they come out, the flowers, how they appear,. . . . I should especially [take not of] the flowers and fruit.” The grass Muhlenbergia was named for Heinrich Muhlenberg. Muhly grasses are beautiful native grasses. They offer two incredible strengths in their plant profile: drought tolerance and visual punch. Muhly grasses are easy-going, and they grow equally well in harsh conditions and perfectly manicured gardens. The Muhly cultivar ‘White Cloud’ offers gorgeous white plumes. When the coveted Pink Muhly blooms, people often stop to inquire as to the name of the beautiful pink grass. Then, Lindheimer’s Muhly makes a fantastic screen, and Bamboo Muhly commands attention when it is featured in containers. All Muhly grasses like well-drained soil and full sun. If you plant them in fall, be sure to get them situated and in the ground at least a month before the first frost. And here’s an interesting side note: Muhlenberg also discovered the bog turtle. In 1801, the turtle was named Clemmys muhlenbergii in his honor.   1818Today is the anniversary of the death of the American physician Caspar Wistar ("Wiss-Star"), the Younger.  His grandfather was also Caspar Wistar, so the Younger distinction helps people tell them apart. Wistar was a Professor of Anatomy at the University of Pennsylvania. In 1777, Caspar Wistar treated the wounded during the battle of Germantown and decided he would pursue medical training. Wistar had some pretty impressive friends: his best friend was probably Thomas Jefferson, and his most famous botany friend was probably Alexander von Humboldt. During his life, every Sunday Night, Wistar would hold a salon - an open house - at his home on the corner of Fourth and Locust Street. His friends would stop by - along with any members of academia, or the elite or high society, along with other accomplished people who happened to be in Philadelphia that evening. They all knew that Wistar's house was the place to go to meet up with the best minds of the day. The botanist Thomas Nuttall named the genus Wisteria in Caspar Wistar's honor (some people say Wistaria to reflect the proper spelling of Wistar's last name. Either is fine because guess what - the misspelling is preserved for all time under the International Code of Botanical Nomenclature). It's like one of my kid's birth certificates - it can be amended, but the original is wrong and will be until the end of time. Wistar died of a heart ailment unexpectedly on January 18, 1818. His final utterance was: "I wish well to all mankind." After Wistar died, his friends continued holding Wistar parties for a core group of 50 members. They would each take turns hosting, and the kept the tradition going for another forty years. Today, Wistar ("Wiss-Star")is the name of The Wistar Institute, the nation's first independent biomedical research center. Today, they focus on cancer, infectious disease & vaccine research to benefit human health.   1985 Record-breaking cold temperatures damaged 90% of Florida's orange and grapefruit crop. Newspaper accounts sounded grim saying: “A nightmare for citrus growers...The fourth killer cold wave in five growing seasons seized Florida's 760,000-acre Citrus Belt on Monday with an icy grip that growers said froze millions of oranges and could destroy thousands of acres of trees already weakened by the disastrous Christmas 1983 freeze. Shocked by lows that fell to the low- and mid-teens throughout the northern two-thirds of the orange belt by Monday morning, growers said the latest in the string of freezes undoubtedly would end the careers of many of the state's 30,000 citrus growers. "It's a nightmare come true: back-to-back 100-year freezes," said Marion County citrus-man John Futch. A 100-year freeze is expected to occur only once every century. All-time low-temperature records were set across the state early Monday, including 19 degrees in Orlando and 17 degrees in Daytona Beach. Farmers as far south as Naples lost fruit and vegetable crops to the numbing cold. Citrus experts with Florida Citrus Mutual, the state's largest growers' organization with more than 15,000 members, said the low temperatures Monday rivaled "Between last night and tonight, I don't think there'll be a tree alive in Hernando County when this is over," Dr. William Croom said Monday morning after surveying his 104-year-old, 110-acre grove on Powell Road. "I'm not going to replant. I'll be 65 in March. That's just too late in life" to start over. As the temperature fell to 15 degrees, Croom's grove foreman, Barney Parrott, and three other workers lighted 300 oil-fueled stack heaters among trees in an 8-acre section in an effort to salvage the healthiest portion of his grove. "We'll be back out tonight, although I don't know if it'll do any good," he said Monday.   Unearthed Words Today’s words are about the lessons we can learn from winter.   Spring passes, and one remembers one’s innocence. Summer passes and one remembers one’s exuberance. Autumn passes and one remembers one’s reverence. Winter passes, and one remembers one’s perseverance. — Yoko Ono, Japanese-Multimedia Artist, Widow of John Lennon   People don't notice whether it's winter or summer when they're happy. — Anton Chekhov, Russian Playwrite & Writer   One kind word can warm three winter months. — Japanese Proverb   “What good is the warmth of summer, without the cold of winter to give it sweetness.” — John Steinbeck, American Author & Nobel Prize Winner   To shorten winter, borrow some money due in spring. — W.J. Vogel   If there were no tribulation, there would be no rest; if there were no winter, there would be no summer. — St. John Chrysostom ("kri-SOSS-tum"), Bishop of Constantinople   "Nature has undoubtedly mastered the art of winter gardening, and even the most experienced gardener can learn from the unrestrained beauty around them." — Vincent A. Simeone ("Sim-EE-OH-nee"), Horticulturist   Grow That Garden Library By Pen & by Spade by David Wheeler This book features thirty-three essays From David Wheeler's passion project known as Hortus magazine (Which I just subscribed to). Hortus provides expert information on plants and gardening, with articles focusing on gardens around the world. The essays explore the various benefits of gardening. They are written by multiple writers who share personal stories and lessons from the garden. This book features essays from Robert Dash (who examines the overlap between gardening and poetry), Rosemary Verey (who shares thoughts on the courtyard gardens of Charleston), Hermia Oliver does the same with Flaubert's gardens; And, Dennis Wood reveals the joy of gardening after retirement. These essays are an excellent source of good gardening advice: how to plant a scent garden ("Stick to a sunny, sheltered spot," advises Stephen Lacey), how to grow blue-hued gentians (seek out an acid soil, counsels Stephen G. Haw). This book came out in 1991. You can get a used copy of By Pen & by Spade by David Wheeler and support the show, using the Amazon Link in today's Show Notes for under $1.   Great Gifts for Gardeners Esschert Design Garden Tool Belt, Gray & Green, $13.18 Adjustable green and gray garden tool apron. Deep pockets, adjustable belt, and compartments for markers make this apron a must for every busy gardener. Tool Belt 13; 26 Inch 1; 482 Inch 13; 26In Perfect For Use In The Garden Or Yard Grey And Green Canvas Tool Belt With Plastic Clasps   Today’s Botanic Spark 1917 Today is the anniversary of the death of the Presbyterian minister, writer, and an American botanist Ellsworth Jerome Hill. Ellsworth was born in Leroy, New York. When Ellsworth was only 20 years old, one of his knees stopped working, and the doctor suggested he study botany. Ellsworth wood crawl from the house to the orchard, where he would pick a few flowers and then crawl back to the house to identify them. And the following year, Ellsworth moved to Mississippi, where it was warmer, and he used two canes to assist with walking. By middle age, Ellsworth met and married a young woman named Milancy Leach - who would become his indispensable helpmate. When he was lame, or when he didn't have the strength to complete all of his tasks as he collected specimens, Milancy would step in and finish the work for him. By the time he was 40, Ellsworth had put his lameness behind him. In the back half of his life, he seemed to be able to manage his physical challenges and, with Milancy’s help, had learned how to cope with the symptoms. In a touching tribute to Ellsworth after his death, the botanist Agnes Chase rote: “Most of these collections were made while he walked on crutches or with two canes. He told me that he carried his vasculum over his shoulder and a camp stool with his crutch or cane in one hand. To secure a plant, he would drop the camp stool, which opened of itself, then he would lower himself to the stool and dig the plant. He recovered from his lameness but often suffered acute pain from cold or wet or overexertion. But this did not deter him from making botanical trips that would have taxed a more robust man – in the Dunes, I have seen him tire out more than one able-bodied man. “ It was Ellsworth Jerome Hill who said, "In studying the flora of a restricted region, no matter how carefully it seems to have been explored, one is frequently surprised by new things...  No region can be regarded as thoroughly explored until every acre of its wild areas at least has been examined. Some plants are so rare or local or grow under such peculiar conditions that a few square rods or even feet may comprise their range."

Every autumn, we owe a debt of gratitude to our trees.   They give our gardens the best gift: leaves.   Over the past decade, there's been a resurgence of interest in the restorative power of leaves in the garden. For some gardeners, this is new news. Yet, we've known about the wonderful contributions of leaves in the garden for a long time.   As proof, here's a little post from the The York Daily  out of York Pennsylvania on October 23, 1879:   "Fallen leaves make excellent compost for the garden."   And, theSunday News out of Lancaster, Pennsylvania from November 16, 1952, wrote this:   "Many city gardeners and suburban farmers... now realize the value of leaves as fertilizer and mulching material and are glad to take the leaves off the Street Departments hands...      This helps solve the problem of what to do with the fallen leaves, but it doesn't help the raking aches."       Brevities #OTD   Today is the birthday of the English watercolorist and founding advocate of the picturesque landscape, William Gilpin, who was born on this day in 1762. As an early headmaster and vicar of the Cheam School, Gilpin taught vegetable, as well as ornamental, gardening to the students. In 1777, Gilpin became the parson at the Boldre church of St. John the Baptist in the New Forest district of Hampshire. The church dates back to the 11th century. Gilpin was a fount of knowledge about the area surrounding Boldre Church and its flora and fauna. Gilpin served as the Boldre church parson until his death in 1804 at the age of 80. Gilpin is buried, alongside his wife, in the church cemetery beside an old maple tree. His inscription reads: "It will be a new joy to meet several of their good neighbors who now lie scattered in these sacred precincts around them."   Gilpin would travel around the English countryside, creating beautiful watercolors of the landscape and keeping journals where he refined his thoughts on the picturesque landscape . Gilpin filled his sketchbooks with drawings and observations on landscapes and how to paint them. Gilpin wrote, "In order to color chastely and harmoniously, use only 3 tints: red, yellow, and blue..."   Gilpin's accounts of his travels were published in guidebooks and created popular interest in natural beauty and the picturesque landscape.  Gilpin's bestselling book, "Observations on the River Wye: And Several Parts of South Wales, Relative Chiefly to Picturesque Beauty: Made in the Summer of the year 1770"  (often referred to as the River Wye guidebook),  brought scads of tourists to the area during the 18th century. Gilpin wrote: "Every distant horizon promises something new; and with this pleasing expectation we follow nature through all her walks."   During his time, Gilpin was an arbiter of artistic taste, and he thought that artists should try to find the most "picturesque" view of a landscape. Gilpin didn't enjoy artificial creations and lines in the garden. He was a fan of more natural-looking landscapes that were often  savage and less domesticated. To Gilpin, the best landscapes offered ruins and mountains along with trees. Gilpin's watercolors were created on site and he wasn't opposed to using a little artistic license to make the scene more compelling; adding a little bridge or tree or making a ruin ever more ruinous. In 1786, Gilpin wrote, "A ruin is a sacred thing. Rooted for ages in the soil; assimilated to it; and become, as it were, a part of it ..."    A simple way to remember the picturesque style, is to remember that Gilpin was a painter and he was seeing the landscape with “a painter’s eye”. The picturesque was a view that was worthy of being painted and Gilpin said it was "that kind of beauty which is agreeable in a picture." The bottom line is that the images were designed to get your attention.  Gilpin wrote: "Our eyes are only glass windows; we see with our imagination."   Gilpin was the first president of The Royal Watercolor Society and he is remembered for his books including one of his most popular called "Forest Scenery" which included 45 watercolors and descriptions of trees and shrubs;  and instructions for how to capture a picturesque effect through the clumping of trees. Gilpin adored trees. He wrote:  "It is no exaggerated praise to call a tree the grandest and most beautiful of all productions on earth!"   For instance, the "roan-tree" was noted for having "glowing berries". Rowan was the common name for the Mountain Ash, also known as "the witch" or "quickening-tree". The origin of the word rowan comes from a german word meaning "to redden" and it refers to the little,  red berries. On the other hand, Gilpin was not a fan of the Hawthorn, writing that it had , "little claim to picturesque beauty... It is but a poor appendage. Its shape is bad. It does not taper and point like the Holly, but is rather a matted, round, heavy bush. Its fragrance indeed is great ; but its bloom, which is the source of that fragrance, is spread over it in too much profusion."  In 1832, Gilpin published Practical Hints upon Landscape Gardening: with some remarks on Domestic Architecture, as connected with scenery,which ran to a second edition in 1835. He wrote it because he said he felt there was little "practical information" in the books available at the time. One of my favorite parts of the book is where he discusses how to get a client to support ideas for their Landscape.   "It has ever appeared to me, that a very essential part of an improver's duty is to explain to the proprietor the principles upon which he suggests any plan of improvement. This, during the progress of the work, not only enhances the pleasure of the proprietor, and assists his general taste, but it also ensures his future care, through the periodical prunings and thinnings which must of necessity take place."   Gilpin encouraged landscapers, (he referred to them as improvers), to educate their clients, to overcome objections and prejudices. To Gilpin's view, educating customers was sufficient; once they understood the general design, they would surely come around.  More quotes from Gilpin:   "The picturesque eye, in quest of beauty, finds it in almost every incident." "The pleasures of the chase are universal. A hare started before dogs is enough to set the whole country in an uproar."           #OTD  On this day in 1777, Caspar Wistar treated the wounded during the battle of Germantown and decided he would pursue  medical training. Wistar ("Wiss-Star")is the names     of The Wistar Institute; the nation's first independent biomedical research center. Today, they focus on cancer, infectious disease & vaccine research to benefit human health. The botanist Thomas Nuttall gave the name Wisteria to the genus in honor of Caspar Wistar. Some people pronounce it "Wis-star-ia" to reflect the proper spelling of Casper Wistar's last name.       #OTD   Today is the birthday of the Master Collector of Botanists, John Hendley Barnhart who was born on this day in 1871. Barnhart was an American botanist who specialized in the biographies of other botanists. Like many botanists, Barnhart came to botany through medicine. After training to be a doctor, he never practiced medicine and instead turned his full-time attention to botany. Barnhart is remembered for his work at the New York Botanical Garden (NYBG) where he served as the Bibliographer of the Garden from 1913 to 1942. An amateur genealogist, his famous biographical index of botanists included over 20,000 cards. Barnhart's strength was Input; he collected vast amounts of information, stored it, and retrieved it for experts when called upon. His obituary stated that scientists all over the world leveraged Barnhart for their research. An article featured in The Nebraska State Journal from December 12, 1919 had a fascinating headline, "Famous Botanists Who Never Breathed". "Dr. Barnhart declares that the subjects of eleven biographical sketches of botanists in Appleton's Cyclopaedia of American biography are figments; that their births, their names, their voyages, their scientific adventures and their numerous books, so solemnly given by title and number of volumes, existed only in the mind of some falsifier of the human record. For instance, an Alexander Daniel Koehler, who, inspired by Humboldt, came to America, lived for seven years at Santa Fe, explored South America and wrote, among many other works, "Flora Brasiliensis," published in four volumes in Berlin in 1821-23."  Barnhart believed that the eleven fake botanist biographies were the work of one person... but we don't know who or why they did it.   The was another fun newspaper account of Barnhart. This one was from The Brooklyn Daily Eagle   from April 27, 1934. It gave an account of a lecture by Barnhart on the wild flowers of North America. He said, "... buttercups and bright red columbines that once covered the countryside are in increasing danger of extinction as a result of the depredations of motorists. The only flowers free from danger are those which, like water lilies and marigolds, are naturally difficult of access. The purplish-white blossoms of mountain laurel are generally conceded to be the loveliest of North American wild flowers. Drosera, (commonly known as the sundews) the only carnivorous Northern flower, that trips and devours tiny insects by means of sticky, porous leaves, is a demure, deceptive yellow blossom. The coy trillium and the strange, bloated pitcher flower are among the curiosities of this part of the world, while the airy white flower genially named Dutchmen's breeches looks the most nonchalant. Certain flower names, like those of the rose and the lily, have come down to us almost unchanged since ancient times, and are practically similar in all European languages."           Unearthed Words   "Come said the wind to  the leaves one day,  Come o're the meadows  and we will play.  Put on your dresses  scarlet and gold,  For summer is gone  and the days grow cold." - A Children's Song of the 1880's     "Trees enrich our lives throughout the year. They reassure us with the rustle of their leaves, give us shade to soothe our overheated bodies and they bring delight to us when we watch birds nest in their boughs. However, it is only during the fall that they wave flamboyant foliage that seems to demand our attention." - Blue Ridge Parkway: A Guide to Trees         Today's book recommendation: The Urban Homestead by Kelly Coyne and Erik Knutzen The 2010 book is the updated version of the best-selling classic. It features a dozen new projects. The New York Times said this book was the "contemporary bible" on Urban Homesteading. This book is an excellent resource. It's an idea book and  that gives you the tools to get started on path to self-sufficiency. It offers fantastic examples of how, no matter the size of your space, you can support yourself and your family in an environmentally-responsible way. The authors, Kelly Coyne and Erik Knutzen, are creators of the blog Root Simple, a green living and self-reliance resource for homesteaders, urban and otherwise. They live in Los Angeles.         Today's Garden Chore Thoroughly wash and inspect your houseplants before bringing them back indoors.  My houseplants get a nice spa day in the kitchen sink when they come back inside for the winter. First, they get a little time to acclimate to the temperature inside before they get their turn at the sink. Then I wash the leaves with sharp streams water and a little dawn dish soap. And don't forget about the bottom and sides of the pot; no need to track in extra dirt or insects.           Something Sweet  Reviving the little botanic spark in your heart   Today's show started with a little Monologue about leaves, and I thought I'd share this adorable little advertisement from WC Landon and Companyin the Rutland Daily Herald out of Vermont From September 27, 1927:   Whether You Save Your Leaves for excellent cover for garden and lawn or whether you burn them you need a good rake to get them together. Here are four different kinds, all good The Japanese Sweep Rake, light and handy, but not for heavy work.......$1.00 The Wood Lawn Rake with 24 teeth, for heavy work .......$1.00 The Hoover Wire Lawn Rake is much favored at ....... 75c The Brume Rake with flat steel teeth, shaped like the Japanese Sweep, priced at .......$1.00   So, there you go. That's a sweet, little summary of Rake options in Vermont in 1927.       Thanks for listening to the daily gardener, and remember: "For a happy, healthy life, garden every day."

Season 2 Episode 17: Training to the Need featuring Community College of Philadelphia & The Wistar Institute | Growing Greater This week we continue with our special series with our Chamber of Commerce for Greater Philadelphia (Chamber)’s Talent Action Team showcasing just how vital talent retention and workforce development initiatives are to this region. First, Dr. Donald Guy Generals, President of Community College of Philadelphia (CCP) chats with Matt Cabrey, Executive Director of Select Greater Philadelphia, a council of the Chamber of Commerce for Greater Philadelphia, about how students are not only obtaining a world class education, but launching their careers through training programs. Then, Brian Keith, Dean of Biomedical Studies from The Wistar Institute explains how they have partnered with CCP to create the Biomedical Technician Training Program; a program designed to prepare community college students for new career opportunities as research assistants and technicians.

Welcome back to another solo episode with me, host Gabrielle Mandel. I talk about what I learned in the next five years working in the fashion industry. With my budding startup, Supra Endura, I applied and got accepted to the fashion business accelerator the Philadelphia Fashion Incubator. I go over what I learned and how I managed to grow my business as a solo entrepreneur. I also started to work for Urban Outfitters and began to teach at Made Institute. I talk about what it was like pitching and then executing collaborations with Urban Outfitters and The Wistar Institute. In 2017 I got offered a full-time design role on Anthropologie’s Home textile team and I talk about how I balance my full-time work with running my business. The episode is full of great creative business take aways and what it is like to really work in the Fashion Industry.

En este nuevo episodio de caminos en ciencia la Dra. Jessie Villanueva nos cuenta su camino empezando en Perú y los múltiples retos que enfrentó hasta llegar al Wistar Institute, donde actualmente lidera un grupo que estudia melanoma.

Jason interviews Dr. Carlo Maley on the ways that Nature has already beaten cancer.   Dr. Maley received his Ph.D. from MIT in computer science (computational biology) in 1998 working with Rodney Brooks and Michael Donoghue (at Harvard at the time), his M.Sc. Zoology (evolutionary theory) from University of Oxford in 1993 working with W.D. Hamilton, and his B.A. in computer science and psychology from Oberlin College in 1991.   He went on to hold faculty positions at the Wistar Institute (2005-2010) and the University of California San Francisco (2010-2015) before joining Arizona State University in 2015.Maley is a Renowned Cancer Biologist, Evolutionary Biologist, and Computational Biologist.  Maley will discuss the findings from his TedxTalks Event: "How Nature Has Already Beat Cancer." (TEDxASU), published on 5/22/16.    Jason looks forward to interviewing Dr. Maley about his research which describes Twelve Examples of Animals Who Have Beat Cancer Through Evolution including such animals such as the elehpant, rhinocerous, giraffe, water buffalo, indian bison, polar bears and others.  Maley's team applies evolutionary and ecological theory to three problems in cancer: (1) Neoplastic progression: the evolutionary dynamics among cells of a tumor that drive progression from normal tissue to malignant cancers, (2) Acquired therapeutic resistance: the evolutionary dynamics by which our therapies select for resistance and we fail to cure cancer, and (3) the evolution of cancer suppression mechanisms in large, long-lived animals like elephants and whales (a problem called Peto's Paradox). They use genomic data mining, phylogenetics, computational modeling, as well as wet lab techniques to solve these problems. In all of this work, their goals are to develop better methods to prevent cancer and improve cancer management.  

Jason interviews Dr. Carlo Maley on the ways that Nature has already beaten cancer.   Dr. Maley received his Ph.D. from MIT in computer science (computational biology) in 1998 working with Rodney Brooks and Michael Donoghue (at Harvard at the time), his M.Sc. Zoology (evolutionary theory) from University of Oxford in 1993 working with W.D. Hamilton, and his B.A. in computer science and psychology from Oberlin College in 1991.   He went on to hold faculty positions at the Wistar Institute (2005-2010) and the University of California San Francisco (2010-2015) before joining Arizona State University in 2015. Maley is a Renowned Cancer Biologist, Evolutionary Biologist, and Computational Biologist.  Maley will discuss the findings from his TedxTalks Event: "How Nature Has Already Beat Cancer." (TEDxASU), published on 5/22/16.    Jason looks forward to interviewing Dr. Maley about his research which describes Twelve Examples of Animals Who Have Beat Cancer Through Evolution including such animals such as the elehpant, rhinocerous, giraffe, water buffalo, indian bison, polar bears and others.   Maley's team applies evolutionary and ecological theory to three problems in cancer: (1) Neoplastic progression: the evolutionary dynamics among cells of a tumor that drive progression from normal tissue to malignant cancers, (2) Acquired therapeutic resistance: the evolutionary dynamics by which our therapies select for resistance and we fail to cure cancer, and (3) the evolution of cancer suppression mechanisms in large, long-lived animals like elephants and whales (a problem called Peto’s Paradox). They use genomic data mining, phylogenetics, computational modeling, as well as wet lab techniques to solve these problems. In all of this work, their goals are to develop better methods to prevent cancer and improve cancer management.  

Dr. Eric Kmiec is Director of the Gene Editing Institute of the Helen F. Graham Cancer and Research Institute at Christiana Care Health System. He also holds faculty appointments at the University of Delaware and the Wistar Institute. Eric and his colleagues are working to develop new ways to treat cancer by destroying the genes that cause cancer cells to be resistant to typical therapies like chemotherapy, radiation, or immunotherapy. Throughout his life, Eric has enjoyed sports. He particularly likes playing baseball and hockey, and he still plays baseball competitively in a league in Philadelphia. Eric also spends much of his time doing landscaping and yardwork. He Received his B.A. in Microbiology from Rutgers University, his M.S. in Cell Biology and Biochemistry from Southern Illinois University, and his Ph.D. in Molecular Biology and Biochemistry from the University of Florida School of Medicine. He conducted postdoctoral research at the University of Rochester before joining the faculty at the University of California, Davis in 1987. Since then, he has served on the faculty of Thomas Jefferson University, the University of Delaware, and Delaware State University. In addition, Eric founded, consulted for, and served as Vice President of Kimeragen, Inc., he was Chief Scientific Advisor for the Genomics Division of Tapestry Pharmaceuticals, was an Eminent Scholar and Director of the Marshall University Institute for Interdisciplinary Research, and also served as Co-Founder, Chief Scientific Officer, and a Board Member of OrphageniX. Eric has received numerous awards and honors over the course of his career, including receipt of the 2012 Proudford Foundation Unsung Hero Award in Sickle Cell Disease, designation as an Honorary Commander of the 436th Air Wing at Dover Air Force Base in 2013 and 2014, and also induction into the Southern Illinois University, Edwardsville Alumni Hall of Fame in 2012. Further, Eric and the team at the Gene Editing Institute were recently awarded the inaugural Life Sciences and Bio Innovation Award from the Philadelphia-Israeli Chamber of Commerce. In our interview, Eric shared his experiences in life and science.

On this episode we talk to Christine Torres, System Vice President, Supply Chain and Biomedical Engineering, Main Line Health in Radnor, Pennsylvania. Chris Torres began her healthcare career as a high-schooler, working in a research lab in a Philadelphia hospital. While still in college, she became certified as a surgical technician and scrubbed in the OR evenings and nights. After graduation, she joined The Wistar Institute, an independent biomedical research firm in Philadelphia, but soon returned to the clinical setting, scrubbing in the OR, primarily for orthopedics and neuro procedures. She assumed additional responsibilities in SPD, logistics and materials management before taking a hiatus from healthcare in 2000, when she joined IKON (now Ricoh), to oversee facilities management in Pennsylvania, New York and New Jersey. She returned to Main Line Health in November 2002. As the system vice president of supply chain management and biomedical engineering, Torres oversees more than 250 employees in biomedical engineering, contracting, inventory control and logistics. The supply chain management team is responsible for approximately $300 million in spend. The program encompasses an in-house biomedical equipment management program, strategic sourcing, supply chain management technology and data analytics, clinical resource management aligned with clinician engagement, and systemized logistics management.

Chief Medical Officer at nanoString Technologies, Dr Alessandra Cesano, brings to light the increasingly critical role of predictive biomarkers in cancer immunotherapy, originally presented during the translational science and new technologies session from 2017’s Immuno-Oncology 360° conference. Save the date for the 4th annual IO360° conference, taking place February 7-9, 2018 in New York City. About Dr Cesano: Alessandra Cesano, MD, PhD has served as CMO at nanoString since July 2015. Prior to joining the company, Dr Cesano was Chief Medical Officer at Cleave Biosciences, Inc. From 2008 to 2014, she served as Chief Medical Officer and Chief Operations Officer at Nodality, Inc, where she built and led the R&D groups, while providing the overall clinical vision for the organization. In addition, Dr Cesano has held various management positions at Amgen, Biogen Idec and SmithKline Beecham Pharmaceuticals, where she helped to advance various oncology drugs through late stage development and FDA approvals. Dr Cesano spent 12 years researching tumor immunology, including nine years at the Wistar Institute, an NCI Basic Cancer Center at the University of Pennsylvania. She also holds membership in several professional and scientific societies, and has been an author on over 100 research publications.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Host: Brian P. McDonough, MD, FAAFP It's widely known that genetics, family history, race, and other factors all play important roles in cancer risk. But what kinds of roles do they play, specifically, and how can we leverage these understandings into better primary care? Dr. Brian McDonough is joined by Dr. Maureen Murphy, research scientist at the Wistar Institute at the University of Pennsylvania. Dr. Murphy has spent the past twenty years studying how genes affect breast cancer risk in women, particularly for African American populations. She discusses her findings on the discovery of p53 protein variants and how this advances the role for precision medicine in treating breast cancer.

Dr. Maureen Murphy is a Professor and Program Leader in the Molecular and Cellular Oncogenesis Program of the Wistar Institute Cancer Center in Philadelphia. She is also the Associate Vice president for Faculty Affairs and Associate Director For Education and Career Development there. Maureen received her B.S. in biochemistry from Rutgers University and a Ph.D. in molecular biology from the University of Pennsylvania School of Medicine. After graduate school, she completed postdoctoral research at Princeton University. Maureen served on the faculty at the Fox Chase Cancer Center before accepting her current position at the Wistar Institute. Maureen is with us today to tell us all about her journey through life and science.

Dr. Stephen C. Marini was educated in basic science and medicine at Hahnemann Medical College in Philadelphia where he received a M.S. in Microbiology and Immunology in 1976.  Doctoral studies followed at the University of Pennsylvania and Pacific Western University with dissertation research on avian tumor viruses accomplished at the Wistar Institute in Philadelphia.  He received his Ph.D. in Microbiology in 1989.  Vitalistic training and professional development occurred at the Pennsylvania College of Chiropractic where he received his D.C. in 1988.  He served as professor of Microbiology at the Pennsylvania College of Chiropractic from 1980-1995 and as Academic Dean from 1990-1993.   As a vitalist trained in classical science and conventional medicine, Dr. Marini appreciates the role of energy/information on an individual's health and healing process.  He recognizes the need for a complementary, patient-centered approach to healing and health care options.  Dr. Steve incorporates this knowledge and belief into his teaching of psychoneuroimmunology and vaccination issues.   Dr. Marini serves on the Boards of the International Chiropractic Pediatric Association (ICPA), the Holistic Pediatric Association (HPA), and the Integrated Healthcare Policy Consortium (IHPC).  For more information, please visit his website at www.marinichiroanded.com.  

Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia.  A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968.  We are still using the same vaccine 40 years later.  Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology.  For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious.  The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome.  Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella.  Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak.  Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries.  In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else.  In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development.

Guest: Anil Vachani Host: Lee Freedman, MD Dr. Anil Vachani, assistant professor of medicine, and director of clinical research in interventional pulmonary services, at the University of Pennsylvania Health System, joins host Dr. Lee Freedman. They talk about Dr. Vachani's exciting work on the development of a blood test that may be useful in distinguishing benign from malignant in patients with lung nodules. Along with researchers at the Wistar Institute in Philadelphia, Dr. Vachani has developed a test utilizing the profiling of gene expression of peripheral blood lymphocyte involved in tumor immunity. Still in the early stages of development, this work has led to a 24 gene 'signature' that has a sensitivity of 85 percent and specificity of 87 percent. Find out how soon this test might be available for clinical use, and other potential applications of this technology in clinical medicine.